var title_f38_1_38928="Oxymetazoline: Patient drug information";
var content_f38_1_38928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxymetazoline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/25/23956?source=see_link\">",
"       Oxymetazoline (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/0/2052?source=see_link\">",
"       Oxymetazoline (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11512 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38928=[""].join("\n");
var outline_f38_1_38928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/25/23956?source=related_link\">",
"      Oxymetazoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/0/2052?source=related_link\">",
"      Oxymetazoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_1_38929="IVUS in patient with CAV";
var content_f38_1_38929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/77518/IVUS_CAV_conv2.mp4?title=IVUS+in+patient+with+CAV\" style=\"width:384px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravascular ultrasound images in a patient with cardiac allograft vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe intimal thickening (green line indicates maximal intimal thickness).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Finn Gustafsson.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38929=[""].join("\n");
var outline_f38_1_38929=null;
var title_f38_1_38930="Gallium citrate Ga-67: Patient drug information";
var content_f38_1_38930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gallium citrate Ga-67: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4978?source=see_link\">",
"     see \"Gallium citrate Ga-67: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13316613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before a test to see parts of the body better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13316595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gallium citrate Ga-67 or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13316597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13316616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13316599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13316615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13316600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17076 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38930=[""].join("\n");
var outline_f38_1_38930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316613\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316595\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316597\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316616\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316599\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316615\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316600\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4978?source=related_link\">",
"      Gallium citrate Ga-67: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_1_38931="Poison ivy fruit";
var content_f38_1_38931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison ivy fruit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cream-colored fruit of poison ivy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38931=[""].join("\n");
var outline_f38_1_38931=null;
var title_f38_1_38932="Azelastine and fluticasone: Patient drug information";
var content_f38_1_38932=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azelastine and fluticasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36341?source=see_link\">",
"     see \"Azelastine and fluticasone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14970004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dymista&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14974801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14974800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890283",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azelastine, fluticasone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14974805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any nose ulcers or sores, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14974806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nosebleed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14974807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Whistling sound when you breathe.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14974803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prime pump before first use by spraying it 6 times or until you see a fine mist.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not used the spray for more than 14 days, you will need to prime the pump with 1 spray or until you see a fine mist.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Close 1 nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head forward a little.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put nose spray tube into other nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       While breathing in, press down once to release spray.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe out from your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3682982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray up the nose only. Do not spray onto the wall joining your two nostrils.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F14974804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F14974808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store upright at room temperature. Do not freeze. Throw away any part not used after 120 sprays.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14974809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86610 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38932=[""].join("\n");
var outline_f38_1_38932=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14970004\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974801\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974800\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974805\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974806\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974807\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974803\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974804\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974808\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974809\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36341?source=related_link\">",
"      Azelastine and fluticasone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_1_38933="Desmosomes squamous CA";
var content_f38_1_38933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intercellular bridges in a squamous cell carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High magnification photomicrograph showing intercellular bridges (desmosomes), which appear as refractile striations between distinct cytoplasmic borders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38933=[""].join("\n");
var outline_f38_1_38933=null;
var title_f38_1_38934="Histiocytic sarcoma";
var content_f38_1_38934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Histiocytic sarcoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38934/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38934/contributors\">",
"     Eric Jacobsen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38934/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38934/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38934/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38934/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/1/38934/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1096489\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histiocytic sarcoma (HS) is an extremely rare non-Langerhans histiocyte disorder of unknown cause that most commonly presents with symptoms due to unifocal or multifocal extranodal tumors. HS may occur as a sporadic illness or may be clonally related to a separate synchronous or metachronous hematologic malignancy, such as follicular lymphoma or acute lymphoblastic leukemia.",
"   </p>",
"   <p>",
"    Histocytic disorders are thought to be derived from mononuclear phagocytic cells (macrophages and dendritic cells) or histiocytes. This group has generally been divided into Langerhans cell histiocytosis and non-Langerhans histiocytosis. Langerhans cell histiocytosis is so named for its presumed derivation from the Langerhans cells, which are specialized dendritic cells found in the skin and mucosa. In contrast, non-Langerhans histiocytoses are thought to be derived from the monocyte-macrophage lineage.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, pathologic features, diagnosis, and management of HS will be presented here. The diagnosis and management of Langerhans cell histiocytosis and other non-Langerhans histiocytic disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/48/35592?source=see_link\">",
"     \"Pulmonary Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32551?source=see_link\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20680?source=see_link\">",
"     \"Erdheim-Chester disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096496\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HS is an extremely rare disease with only a few hundred cases reported in the literature. HS has been diagnosed in all age groups, but is most common in adults. In two case series, the median ages at diagnosis were 46 and 55 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There is no apparent gender difference.",
"   </p>",
"   <p>",
"    There are no known environmental or hereditary genetic factors predisposing to the development of HS. HS can occur as an isolated disease or in the context of other hematologic neoplasms, such as follicular lymphoma, myelodysplasia, or acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/2\">",
"     2",
"    </a>",
"    ]. When HS occurs in the context of another hematologic malignancy, the two entities are often clonally related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Of importance, tumors with pathologic features consistent with histiocytic sarcoma occurring in the context of acute monocytic leukemia are",
"    <strong>",
"     not",
"    </strong>",
"    considered histiocytic sarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096510\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of HS remains unclear. HS is not a true sarcoma but is derived from cells of the",
"    <span class=\"nowrap\">",
"     monocytes/macrophage",
"    </span>",
"    system. HS has been described in association with a number of hematologic neoplasms, most commonly acute lymphoblastic leukemia (ALL) and follicular lymphoma (FL). In addition, cases have been reported in patients with mediastinal germ cell tumors, such as malignant teratomas, suggesting a possible derivation of such tumors from pluripotent germ cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempts to establish clonality have had varied results, and although occasional cytogenetic aberrations have been identified, none are characteristic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some cases of HS associated with lymphoid neoplasms, the HS has been shown to originate from the same clone that gave rise to the lymphoid neoplasm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a landmark study of eight patients with both FL and HS (seven patients) or interdigitating dendritic cell sarcoma (one patient), all eight possessed the t(14;18) either by fluorescence in situ hybridization (FISH) or by polymerase chain reaction (PCR) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/6\">",
"       6",
"      </a>",
"      ]. Five HS lesions were metachronous, developing two months to 12 years after the follicular lymphoma, while the FL and HS were synchronous in three cases.",
"     </li>",
"     <li>",
"      In a large study of sporadic HS, 9 of 23 cases (39 percent) demonstrated clonal immunoglobulin (Ig) heavy chain (with or without Ig kappa) gene rearrangements, while two (9 percent) cases showed only clonal Ig kappa gene rearrangements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/7\">",
"       7",
"      </a>",
"      ]. One case showed t(14;18) by PCR and FISH analysis showed the resulting",
"      <span class=\"nowrap\">",
"       IGH/BCL2",
"      </span>",
"      fusion in the neoplastic histiocytes. All cases of Ig heavy chain and Ig kappa positive HS were negative for B cell-associated transcription factors such as PAX5 and BOB.1, though four of seven were positive for Oct2.",
"     </li>",
"     <li>",
"      Human and mouse HS tumors have demonstrated genetic or epigenetic inactivation of PTEN, p16(INK4A), and p14(ARF), but how or why these changes occur remains unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28093350\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of HS varies depending upon the organs involved. Most patients present with symptoms due to unifocal or multifocal extranodal disease, most commonly involving the intestinal tract, skin, and soft tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/9\">",
"     9",
"    </a>",
"    ]. However, there is no characteristic pattern of organ system involvement and any organ may be involved including bone, lymph nodes, skin, liver, spleen, lung and the central nervous system. Solitary involvement of the lymph nodes is seen in less than 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Organ involvement may be asymptomatic and discovered at the time of radiographic imaging. More commonly, patients present with a palpable mass lesion, symptoms related to compression of surrounding organs (eg, intestinal obstruction), or systemic complaints (eg, fevers and weight loss). Skin involvement has numerous potential manifestations ranging from rash to tumorous growths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/9\">",
"     9",
"    </a>",
"    ]. Laboratory abnormalities depend on the organ system affected. Cytopenias are seen in approximately one-third of cases, a minority of which will demonstrate hemophagocytosis on bone marrow biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28093415\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies of involved tissue demonstrate an infiltrative process with a diffuse growth pattern and effacement of the normal architecture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/9\">",
"     9",
"    </a>",
"    ]. When involved, the lymph nodes, bone marrow, and spleen demonstrate sinusoidal infiltration and parenchymal involvement. Skin biopsies do not demonstrate epidermotropism.",
"   </p>",
"   <p>",
"    The tumor is primarily comprised of non-cohesive large cells (eg, nuclei at least twice the size of a small lymphocyte and larger than the nucleus of a tissue macrophage) that are polygonal or ovoid with focal spindling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/2\">",
"     2",
"    </a>",
"    ]. The cells have abundant eosinophilic cytoplasm that may contain fine vacuoles. The nuclei are pleomorphic and slightly eccentric with moderately dispersed chromatin and one or more small, but prominent nucleoli. Occasionally, the neoplastic cells have a foamy (xanthomatous) appearance.",
"   </p>",
"   <p>",
"    Hemophagocytosis, tumor giant cells, or a prominent inflammatory infiltrate may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Tissue necrosis is not prominent, but may be seen focally in a minority of cases.",
"    <strong>",
"    </strong>",
"    Occasionally a prominent inflammatory infiltrate obscures the less abundant tumor cells. Birbeck granules (a seminal finding in Langerhans cell histiocytosis) and cellular junctions are absent on electron microscopy.",
"   </p>",
"   <p>",
"    On immunohistochemistry, the cells typically express CD68, lysozyme, CD4 and CD163, but do not express specific T and B cell markers, myeloid cell markers (eg, myeloperoxidase, CD33), CD1a, S100 protein or epithelial markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ]. Staining for lysozyme is usually granular with accentuation of the Golgi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T cell receptor (TCR) and immunoglobulin genes are usually germline, but clonal rearrangements of antigen receptor genes have been identified in some cases. (See",
"    <a class=\"local\" href=\"#H1096510\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096517\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HS is diagnosed based upon the pathologic evaluation of involved tissue interpreted within the clinical context [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/9\">",
"     9",
"    </a>",
"    ]. HS can be difficult to diagnose since it is a very rare disease that can affect many organ systems. An excisional or incisional biopsy of affected tissue is generally preferred, when possible, over a fine needle aspirate or core needle biopsy.",
"   </p>",
"   <p>",
"    HS must be distinguished from other histiocytic and dendritic cell disorders, metastatic solid or hematopoietic neoplasms, primary familial lymphohistiocytic disorders, and acquired causes of hemophagocytic macrophage activation syndromes. Of importance, tumors with pathologic features consistent with histiocytic sarcoma occurring in the context of acute monocytic leukemia are",
"    <strong>",
"     not",
"    </strong>",
"    considered histiocytic sarcoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Langerhans cell histiocytosis &mdash; Langerhans cell histiocytosis (LCH) and HS are both histiocytic diseases that can involve multiple sites. The two entities can usually be distinguished by morphologic and immunohistochemical evaluation. Unlike Langerhans cell histiocytosis, HS tumor cells do not express CD1a or S100. Birbeck granules, a seminal finding in Langerhans cell histiocytosis, are absent in HS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemophagocytic lymphohistiocytosis &mdash; Hemophagocytic lymphohistiocytosis and the related macrophage activation syndrome are systemic disorders that demonstrate tissue infiltration by non-neoplastic histiocytes. While both disorders may demonstrate hemophagocytosis, phagocytic activity is much more common in hemophagocytic lymphohistiocytosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"       \"Hemophagocytic lymphohistiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphoma &mdash; Morphologically, HS resembles diffuse large cell lymphoma or anaplastic large cell lymphoma. However, these entities can usually be easily distinguished from HS by immunohistochemistry. HS does not express B or T cell markers (eg, myeloperoxidase, CD33) and T cell receptor and immunoglobulin genes are usually germline. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25337?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metastatic carcinoma &mdash; Morphologically, lymph node involvement with carcinoma may resemble HS in that both tumors are comprised of large atypical cells. Carcinoma can be readily distinguished from HS by the demonstration of cytokeratin upon staining.",
"     </li>",
"     <li>",
"      Metastatic melanoma &mdash; Both melanoma and HS have large atypical cells and can involve multiple organ systems. However, unlike HS, melanoma is positive for S100, HMB-45,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Melan A. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link\">",
"       \"Pathologic characteristics of melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096531\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best treat patients with HS, the initial evaluation must confirm the histologic diagnosis, the extent and sites of disease, and the performance status of the patient. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with HS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Laboratory studies include a complete blood count, serum electrolytes, chemistries with liver and renal function and electrolytes.",
"     </li>",
"     <li>",
"      Computed tomography (CT) or a combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      to document organ involvement. HS appears to be FDG-avid, at least in small case series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bone marrow biopsy for patients with cytopenias or findings suggestive of hemophagocytosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096538\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standardized therapy for HS and patients should be encouraged to enroll in a clinical trial if one is available. Outside of a clinical trial, treatment options include surgery, radiotherapy, and systemic chemotherapy. The choice among these options is primarily made based upon the extent of disease. Multisystem disease and or a solitary tumor greater than 3.5 cm seem to carry the worst prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096545\">",
"    <span class=\"h2\">",
"     Unifocal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal treatment regimen for patients with unifocal HS is unknown. Data from the published literature are limited to small case series and single-case reports. In addition, the natural history of HS is largely unknown and is likely variable. For patients with unifocal HS, we suggest surgical resection plus adjuvant radiation therapy. Though the optimal radiation dose and field are unknown, we favor an approach similar to that utilized for clinically aggressive non-Hodgkin lymphomas, such as diffuse large B cell lymphoma (eg, involved field radiation therapy at 45 to 50 Gy). There is no clear role for adjuvant chemotherapy in this setting.",
"   </p>",
"   <p>",
"    The largest case series included 14 patients presenting with unifocal extranodal HS treated at a single institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgical resection data was available for 12 patients: six tumors were excised with wide margins, four were excised with minimal margins (one with positive margins), and two were biopsied, but not excised. The following describes the variability of treatment and outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five patients were treated with surgical resection alone. Of these, two developed distant spread within three to four months. Two patients were alive with no sign of recurrence at short follow-up. The fifth patient developed local recurrence at six months that was treated with further resection and radiation therapy and had not recurred again at 11 years of follow-up.",
"     </li>",
"     <li>",
"      Three patients were treated with surgical resection plus adjuvant radiation therapy. None have recurred locally. One developed distant recurrences at 17 and 26 months that were treated with further resection. All three patients were alive with no evidence of disease at a median follow-up of 22 months.",
"     </li>",
"     <li>",
"      Six patients were treated with adjuvant chemotherapy (primarily CHOP:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ). Two patients developed distant spread within weeks, one of whom was successfully treated with further chemotherapy. Two were alive with no evidence of disease at median of 16 months of follow-up. Two patients did not have adequate follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon this data and our clinical experience, we prefer surgical resection with adjuvant radiation therapy. This approach appears to provide good local control while minimizing toxicity. Patients who undergo an initial surgical resection and then experience an isolated site of recurrence may be considered for serial resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096552\">",
"    <span class=\"h2\">",
"     Multisystem disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multisystem involvement appear to have a more aggressive clinical course than those with unifocal disease. Given the rarity of this disease, there are no large prospective trials. Data regarding treatment are limited to small case series and single-case reports. For patients with multisystem involvement of HS, we suggest the use of combination chemotherapy. Surgical intervention is limited to diagnostic biopsies and the management of complications such as perforation, obstruction, or intractable bleeding. There is no clear role for adjuvant radiation therapy in this setting.",
"   </p>",
"   <p>",
"    The ideal chemotherapy regimen for HS is unknown. Most clinicians use regimens designed for patients with clinically aggressive lymphomas, such as diffuse large B cell lymphoma. The two most commonly used regimens are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      (ICE) &mdash; Toxicity data come from the use of ICE in other malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/15\">",
"       15",
"      </a>",
"      ]. Hematologic toxicity is universal with 35 percent of patients requiring transfusion of blood products. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      nonhematologic side effects include infection (23 percent) and nephrotoxicity (1 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CHOP) &mdash; Toxicity data come from the use of CHOP in other malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/16\">",
"       16",
"      </a>",
"      ]. Hematologic toxicity is common, but less than 20 percent require transfusion of blood products. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      nonhematologic toxicities are infection (20 percent), lung toxicity (10 percent), and neurologic toxicity (9 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two regimens have not been compared directly for the treatment of HS. For patients under age 60 with a good performance status, we prefer six cycles of ICE chemotherapy. Eight cycles of CHOP chemotherapy is an acceptable alternative and is generally preferred for older patients who are unlikely to tolerate ICE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/1\">",
"     1",
"    </a>",
"    ]. This preference for ICE over CHOP is primarily because ICE is a more aggressive chemotherapy regimen than CHOP and would theoretically have a greater potential for response in HS (an entity that is often resistant to chemotherapy). Patients who cannot tolerate multiagent chemotherapy (ie, ICE or CHOP) can be treated with single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    modeled after the Histiocyte Society treatment protocol for Langerhans histiocytosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with relapsed or refractory multisystem disease are generally treated with systemic chemotherapy with plans to proceed to allogeneic hematopoietic cell transplantation (HCT) if they achieve a subsequent remission. Although there is a paucity of data to support the use of allogeneic HCT in this setting, conventional chemotherapy regimens provide only transient disease control in the majority of patients with relapsed or refractory HS. Allogeneic HCT is performed in an attempt to provide more intensive chemotherapy and a potential graft-versus-tumor effect. Patients who are not candidates for allogeneic HCT may respond to high dose chemotherapy followed by autologous HCT rescue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Radiation therapy may be used for local palliation.",
"   </p>",
"   <p>",
"    The ideal chemotherapy regimen for relapsed or refractory HS is unknown, but in general regimens that contain non-cross resistant drugs are used. As such, patients initially treated with ICE may be considered for treatment with CHOP. There are case reports of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38934/abstract/20\">",
"     20",
"    </a>",
"    ] showing activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096559\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be clinically assessed a minimum of every three to six months or more frequently as symptoms and organ dysfunction require. The frequency of imaging is dictated by baseline disease status, organ involvement, and requirement for ongoing treatment. Affected organs should be imaged every three to six months until stability is documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096566\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment in a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the National Cancer Institute or from the",
"    <a class=\"external\" href=\"file://www.histiocytesociety.org/site/c.mqISL2PIJrH/b.3809123/k.BD72/Home.htm\">",
"     Histiocyte Society",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1096573\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histiocytic sarcoma (HS) is a rare histiocyte disorder that can present as unifocal or multifocal disease affecting nearly any organ system. (See",
"      <a class=\"local\" href=\"#H1096496\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1096510\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of patients with HS varies depending upon the sites of involvement. Most patients present with symptoms due to unifocal or multifocal extranodal disease, most commonly involving the intestinal tract, skin, and soft tissues. (See",
"      <a class=\"local\" href=\"#H28093350\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HS is diagnosed based upon the pathologic evaluation of involved tissue interpreted within the clinical context. HS can be difficult to diagnose since it is a very rare disease and can affect many organ systems. An excisional or incisional biopsy of an affected organ is generally preferred, when possible. (See",
"      <a class=\"local\" href=\"#H28093415\">",
"       'Pathologic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1096517\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no standard treatment regimen for patients with HS and patients should be encouraged to enroll in a clinical trial. We use the following approach for the management of patients outside of a clinical trial (see",
"      <a class=\"local\" href=\"#H1096566\">",
"       'Clinical trials'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with unifocal disease we suggest surgical excision with adjuvant radiotherapy, if possible, depending on location and extent of disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If radiation is not feasible or would be too toxic, post-operative observation is reasonable. Patients may have serial unifocal recurrences over time and repeat surgical excision",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiotherapy is reasonable in these instances. (See",
"      <a class=\"local\" href=\"#H1096545\">",
"       'Unifocal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with multifocal disease, we suggest aggressive multiagent chemotherapy with six cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (ICE) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CHOP) is an acceptable alternative for those who cannot tolerate ICE. Glucocorticoids, single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and single agent etoposide are generally reserved for patients who cannot tolerate combination chemotherapy. (See",
"      <a class=\"local\" href=\"#H1096552\">",
"       'Multisystem disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allogeneic hematopoietic cell transplantation should be considered for patients who have relapsed or refractory disease that achieve a remission with salvage therapy. (See",
"      <a class=\"local\" href=\"#H1096552\">",
"       'Multisystem disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/1\">",
"      Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol 2004; 28:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/2\">",
"      Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/3\">",
"      Castro EC, Blazquez C, Boyd J, et al. Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol 2010; 13:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/4\">",
"      Wang E, Hutchinson CB, Huang Q, et al. Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. Leuk Lymphoma 2010; 51:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/5\">",
"      deMent SH. Association between mediastinal germ cell tumors and hematologic malignancies: an update. Hum Pathol 1990; 21:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/6\">",
"      Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood 2008; 111:5433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/7\">",
"      Chen W, Lau SK, Fong D, et al. High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas. Am J Surg Pathol 2009; 33:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/8\">",
"      Carrasco DR, Fenton T, Sukhdeo K, et al. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell 2006; 9:379.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/10\">",
"      Oka K, Nakamine H, Maeda K, et al. Primary histiocytic sarcoma of the spleen associated with hemophagocytosis. Int J Hematol 2008; 87:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/11\">",
"      Vos JA, Abbondanzo SL, Barekman CL, et al. Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol 2005; 18:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/12\">",
"      Yoshida C, Takeuchi M. Histiocytic sarcoma: identification of its histiocytic origin using immunohistochemistry. Intern Med 2008; 47:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/13\">",
"      Mikami M, Sadahira Y, Suetsugu Y, et al. Monocyte/Macrophage-specific marker CD163+ histiocytic sarcoma: case report with clinical, morphologic, immunohistochemical, and molecular genetic studies. Int J Hematol 2004; 80:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/14\">",
"      Yaman E, Ozturk B, Erdem O, et al. Histiocytic sarcoma: PET-CT evaluation of a rare entity. Ann Nucl Med 2008; 22:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/15\">",
"      Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:4184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/16\">",
"      Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/17\">",
"      Mainardi C, D'Amore ES, Pillon M, et al. A case of resistant pediatric histiocytic sarcoma successfully treated with chemo-radiotherapy and autologous peripheral blood stem cell transplant. Leuk Lymphoma 2011; 52:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/18\">",
"      Gergis U, Dax H, Ritchie E, et al. Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature. J Clin Oncol 2011; 29:e251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/19\">",
"      Abidi MH, Tove I, Ibrahim RB, et al. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol 2007; 82:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38934/abstract/20\">",
"      Shukla N, Kobos R, Renaud T, et al. Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. Cancer 2012; 118:3719.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16411 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38934=[""].join("\n");
var outline_f38_1_38934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1096573\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096489\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096496\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096510\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28093350\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28093415\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096517\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096531\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096538\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1096545\">",
"      Unifocal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1096552\">",
"      Multisystem disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096559\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096566\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1096573\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20680?source=related_link\">",
"      Erdheim-Chester disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32551?source=related_link\">",
"      Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/48/35592?source=related_link\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_1_38935="Estradiol (topical): Drug information";
var content_f38_1_38935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estradiol (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/34/40485?source=see_link\">",
"    see \"Estradiol (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8018271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8018309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Estrace&reg;;",
"     </li>",
"     <li>",
"      Estring&reg;;",
"     </li>",
"     <li>",
"      Vagifem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8018310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Estrace&reg;;",
"     </li>",
"     <li>",
"      Estring&reg;;",
"     </li>",
"     <li>",
"      Vagifem&reg;;",
"     </li>",
"     <li>",
"      Vagifem&reg; 10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8091963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8018376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All dosage needs to be adjusted based upon the patient's response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vulvar and vaginal atrophy associated with menopause:",
"     </b>",
"     Intravaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaginal cream (Estrace&reg;): Insert 2-4 g/day intravaginally for 1-2 weeks, then gradually reduce to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the initial dose for 1-2 weeks, followed by a maintenance dose of 1 g 1-3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaginal ring (Estring&reg;): 2 mg intravaginally; following insertion, ring should remain in place for 90 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaginal tablet (Vagifem&reg;): Initial: Insert 1 tablet (10 mcg) once daily for 2 weeks; Maintenance: Insert 1 tablet twice weekly",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8018377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8018415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estrace&reg;: 0.1 mg/g (42.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ring, vaginal, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estring&reg;: 2 mg (1s) [total estradiol 2 mg; releases 7.5 mcg/day over 90 days]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, vaginal, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vagifem&reg;: 10 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8018312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8018380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal ring: Exact positioning is not critical for efficacy; however, patient should not feel anything once inserted. In case of discomfort, ring should be pushed further into vagina. If ring is expelled prior to 90 days, it may be rinsed off and reinserted. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion. If vaginal infection develops, Estring&reg; should be removed; reinsert only after infection has been appropriately treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal tablet: Insert tablet with supplied applicator at the same time each day. Once inserted, press plunger until fully depressed, then remove applicator and discard. If tablet comes out of applicator prior to insertion, do not replace; use a new tablet filled applicator instead.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8018313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vulvar and vaginal atrophy associated with menopause",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8018307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate [topical]; Strength of recommendation - weak [topical]).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Estring [U.S., Canada, and multiple international markets] may be confused with Estrena [Finland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8018323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hypertension, leg edema, MI, stroke, syncope, venous thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (4%), anxiety, migraine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Angioedema, chloasma, dermatitis, erythema multiforme, erythema nodosum, hemorrhagic eruption, hirsutism, loss of scalp hair, melasma, pruritus, rash, skin hypertrophy, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (2%), breast pain (1%), breast cancer, breast enlargement, breast tenderness, carbohydrate tolerance decreased, endometrial carcinoma, endometrial hyperplasia, fibrocystic breast changes, galactorrhea, hypocalcemia, libido changes, nipple discharge, ovarian cancer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (4%), diarrhea (5%), nausea (3%), dyspepsia, flatulence, gastritis,  hemorrhoids, toothache, weight changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Leukorrhea (7%), cervical ectropion changes, cervical secretion changes, cystitis, dysmenorrhea, dysuria, genital eruption, urinary incontinence, uterine leiomyomata change, vaginal bleeding pattern change (including abnormal flow, breakthrough bleeding, spotting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vaginal: Trauma from applicator insertion may occur in women with severely atrophic mucosa; burning, discomfort, hemorrhage, moniliasis, pain, pruritus, vaginitis, vulvovaginal infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Porphyria aggravated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (6% to 7%), arthritis (4%), arthralgias (3%), skeletal pain (2%), leg cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, retinal vascular thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory tract infection: (5%), sinusitis (4%), pharyngitis (1%), asthma exacerbation, bronchitis, pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid/anaphylactic reactions, flu-like syndrome (3%), hypersensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Bowel obstruction (ring), ring adherence to vaginal wall (ring), toxic shock syndrome (ring)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8018319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema or anaphylactic reaction to estradiol or any component of the formulation; undiagnosed abnormal vaginal bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast (known, suspected or history of); estrogen-dependent tumor; hepatic dysfunction or disease; known protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8018320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; discontinue use if pancreatitis occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroidism: Use caution in patients with hypoparathyroidism; estrogen-induced hypocalcemia may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal ring: Use may not be appropriate in women with narrow vagina, vaginal stenosis, vaginal infections, cervical prolapse, rectoceles, cystoceles, or other conditions which may increase the risk of vaginal irritation, ulceration, or increase the risk of expulsion. Ring should be removed in case of ulceration, erosion, or adherence to vaginal wall; do not reinsert until healing is complete. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Low-dose intravaginal estrogen may be appropriate for use in the management of vaginal symptoms, lower urinary tract infections, and dyspareunia; in addition, evidence has shown that vaginal estrogens (particularly at estradiol doses of &lt;25 mcg twice weekly) in the treatment of vaginal dryness is safe and effective in women with breast cancer (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"     Systemic absorption occurs following vaginal use; warnings, precautions, and adverse events observed with oral therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: Moderate-to-severe symptoms of vulvar and vaginal atrophy include vaginal dryness, dyspareunia, and atrophic vaginitis. Use caution applying topical products to severely atrophic vaginal mucosa. Local abrasion caused by the vaginal applicator has been reported in women with severely atrophic vaginal mucosa.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8018327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C8 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8018328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8018315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, the use of estrogen and progestin as in combination hormonal contraceptives has not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8018317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8018318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogen has been shown to decrease the quantity and quality of human milk; use only if clearly needed; monitor the growth of the infant closely.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8018417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Estrace Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/g (42.5 g): $157.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ring",
"     </b>",
"     (Estring Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (1): $255.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vagifem Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mcg (8): $85.73",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8018388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy. Assess need for therapy at 3- to 6-month intervals.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Estring (AT, CH, DE, DK, FI, NL, NO, SG, ZA);",
"     </li>",
"     <li>",
"      Oestring (SE);",
"     </li>",
"     <li>",
"      Vagifem (AT, AU, BE, BG, CH, CL, CN, CZ, DE, DK, EE, FI, GB, GR, HK, HN, IE, IL, IT, NL, NO, NZ, PH, PL, PT, SE, SG, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8092009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In studies for vulvar and vaginal atrophy in postmenopausal women, local estrogens have been shown to reduce vaginal pH levels and mature the vaginal and urethral mucosa after 12 weeks of therapy, thereby improving vaginal dryness and mucosal atrophy.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8018369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Average serum estradiol concentrations (C",
"     <sub>",
"      avg",
"     </sub>",
"     ) vary by product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaginal: Vaginal absorption is typically low; any contribution to circulating estradiol concentrations via systemic absorption does not exceed normal postmenopausal ranges (Ulrich, 2010; Weisberg, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Estring&reg;: Average steady state serum concentrations decrease from 11.2 pg/mL at 48 hours to 8 pg/mL at 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vagifem&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 10.9 pg/mL on day 1, 5.5 pg/mL on day 83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributed; high concentrations in the sex hormone target organs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Bound to sex hormone-binding globulin and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol. Sulfate conjugates are the primary form found in postmenopausal women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Primarily urine (as estradiol, estrone, estriol and their glucuronide and sulfate conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Labrie F, Cusan L, Gomez JL, et al, &ldquo;Effect of One-Week Treatment With Vaginal Estrogen Preparations on Serum Estrogen Levels in Postmenopausal Women,&rdquo;",
"      <i>",
"       Menopause",
"      </i>",
"      , 2009, 16(1):30-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/18820592/pubmed\" id=\"18820592\" target=\"_blank\">",
"        18820592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society (NAMS), ''The Role of Local Vaginal Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women: 2007 Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2007,14(3 Pt 1):355-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/17438512/pubmed\" id=\"17438512\" target=\"_blank\">",
"        17438512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simon J, Nachtigall L, Ulrich LG, et al, \"Endometrial Safety of Ultra-Low-Dose Estradiol Vaginal Tablets,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 116(4):876-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/20859151/pubmed\" id=\"20859151\" target=\"_blank\">",
"        20859151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ulrich LS, Naessen T, Elia D, et al, &ldquo;Endometrial Safety of Ultra-Low-Dose Vagifem 10 microg in Postmenopausal Women With Vaginal Atrophy,&rdquo;",
"      <i>",
"       Climacteric",
"      </i>",
"      , 2010, 13(3):228-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/20423243/pubmed\" id=\"20423243\" target=\"_blank\">",
"        20423243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weisberg E, Ayton R, Darling G, et al, &ldquo;Endometrial and Vaginal Effects of Low-Dose Estradiol Delivered by Vaginal Ring or Vaginal Tablet,&rdquo;",
"      <i>",
"       Climacteric",
"      </i>",
"      , 2005, 8(1):83-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/1/38935/abstract-text/15804736/pubmed\" id=\"15804736\" target=\"_blank\">",
"        15804736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9121 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38935=[""].join("\n");
var outline_f38_1_38935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018271\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018309\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018310\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8091963\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018376\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018377\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018415\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018312\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018380\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018313\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018307\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018323\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018319\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018320\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018327\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018328\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018315\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018317\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018318\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018417\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018388\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707700\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8092009\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018369\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9121\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9121|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/25/14746?source=related_link\">",
"      Estradiol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/58/38824?source=related_link\">",
"      Estradiol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/35/35383?source=related_link\">",
"      Estradiol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/34/40485?source=related_link\">",
"      Estradiol (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_1_38936="Management and outcome of isolated atrial septal defects in children";
var content_f38_1_38936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and outcome of isolated atrial septal defects in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38936/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38936/contributors\">",
"     G Wesley Vick, III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38936/contributors\">",
"     Louis I Bezold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38936/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38936/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38936/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38936/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/1/38936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital defects of the atrial septum are common, accounting for approximately 7 percent of congenital heart disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/1\">",
"     1",
"    </a>",
"    ]. They can occur in several different anatomic portions of the atrial septum, and the location of the defect generally reflects the abnormality of embryogenesis that led to the anomaly (",
"    <a class=\"graphic graphic_figure graphicRef52106 \" href=\"mobipreview.htm?7/36/7748\">",
"     figure 1",
"    </a>",
"    ). An atrial septal defect (ASD) can be isolated or can be associated with other congenital cardiac abnormalities. The sizes of ASDs are variable, and their functional consequences are related to the anatomic location of the defect, its size, and the presence or absence of other cardiac anomalies.",
"   </p>",
"   <p>",
"    The natural history, management, and outcomes of children with an isolated ASD will be reviewed here. The pathophysiology, clinical features, identification, and assessment of an isolated ASD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secundum ASDs can close spontaneously, remain unchanged, or enlarge. Spontaneous closure, or a decrease in size, is most likely to occur in defects less than 7 to 8 mm in diameter and with younger age at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], as illustrated by the following studies in which serial echocardiographic studies were performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 101 infants diagnosed at a mean age of 26 days with an average follow-up of nine months, spontaneous closure occurred in all 32 ASDs &lt;3 mm in diameter, in 87 percent of 3 to 5 mm ASDs, in 80 percent of 5 to 8 mm ASDs, and in none of the four infants with defects larger than 8 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 200 children diagnosed at a mean age of 5 months (range 0.1 month to 13.9 years) who were followed for a mean 3.5 years (range 0.5 to 9.4 years), spontaneous closure or decreased size &lt;3mm in diameter was observed in 69 of 81 patients (85 percent) with a 4 to 5 mm ASD, in 36 of 56 (64 percent) with a 6 to 7 mm ASD, in 15 of 41 (36 percent) with a 8 to 10 mm ASD, and in 22 patients with an ASD &gt;10 mm, there was no spontaneous resolution but two had a defect that regressed to &lt;3mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/3\">",
"       3",
"      </a>",
"      ]. Children less than one year of age compared to older children were more likely to experience spontaneous resolution (39 versus 19 percent). Surgical or transcatheter closure was required in 11, 32, and 77 percent of patients with defects of 4 to 5 mm, 6 to 7 mm, and &gt;10 mm, respectively.",
"     </li>",
"     <li>",
"      A fourth report evaluated 104 children who were diagnosed at a mean age of 4.5 years and followed for a mean of three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/5\">",
"       5",
"      </a>",
"      ]. &nbsp;Among 34 patients with a small ASD (&gt;3 to &lt;6 mm), three defects closed spontaneously, seven increased to moderate size, and three increased to large size. Among 40 patients with a moderate ASD (&ge;6 to &lt;12 mm), three defects became small while eight became large. Among 30 patients with large defects (&ge;12 mm), all remained large. Overall, ASD grew larger in 68 patients (65 percent); approximately one-half had more than a 50 percent increase in diameter, and thirteen increased to a size that was too large (&ge;20 mm) for transcatheter closure. Enlargement of the lesions was thought to reflect increased blood flow across the defect and the compliance of the atrial septum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower rate of spontaneous closure in the third study compared to those of the previous reports is presumably related to the older age of patients at initial diagnosis (mean 4.5 years). Most patients with ASDs diagnosed early in childhood experience closure by this age. However, closure sometimes occurs later, a finding illustrated by a study that examined the course of children with secundum ASD diagnosed at a mean age of 1.3 years, who were followed for at least 10 years or until documented closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/6\">",
"     6",
"    </a>",
"    ]. The ASD closed spontaneously in 17 of 30 patients by a mean age of 8.4 years. Of the remaining children, seven remained asymptomatic at an average age of 14.1 years, with defects that were 1 to 6 mm diameter, and six required surgical closure because the ASD enlarged and became symptomatic.",
"   </p>",
"   <p>",
"    In many patients with uncorrected moderate to large ASDs, left-to-right shunting increases with age. As a result, the frequency of heart failure accompanied by fluid retention, hepatomegaly, and elevated jugular venous pressure increases with advancing age. Most such patients become symptomatic before 40 years of age. Common symptoms are palpitations reflecting atrial arrhythmias (the most frequent presenting symptom), exercise intolerance, dyspnea, and fatigue. The arrhythmias are thought to result from stretching of the atria by the increased shunting. In some patients, exercise intolerance may develop as early as the second decade of life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The right-sided volume overload associated with an ASD is usually well tolerated for years. Pulmonary vascular disease develops in about 10 percent of older patients with isolated ASDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/7\">",
"     7",
"    </a>",
"    ], but this complication is rare in childhood and adolescence. In a retrospective study over a 10-year period from two tertiary centers, only 8 of 355 pediatric patients (2 percent) with isolated ASD had severe pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/8\">",
"     8",
"    </a>",
"    ]. These eight infants (six with secundum and two with primum ASD) had elevated pulmonary arterial pressures (PAP) of 50 to 100 percent of systemic pressure and were operated within the first year of life with subsequent normalization of PAP.",
"   </p>",
"   <p>",
"    Pulmonary arteriopathy causes the symptoms and signs of the Eisenmenger syndrome, including cyanosis from right-to-left shunting, dyspnea with exertion, and clubbing of the fingers and toes. Progressive pulmonary hypertension can occur after closure of the defect, even in patients with normal pulmonary hemodynamics at the time of surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for isolated secundum ASD is closure of the defect, which can be achieved by a surgical or percutaneous transcatheter approach. The timing of closure depends upon the presence of associated symptoms and the likelihood of spontaneous closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with a patent foramen ovale (PFO) or a very small ASD do not require specific pediatric cardiology follow-up. The child in whom a clinically significant ASD is detected should be followed by a pediatric cardiologist on an annual or biannual basis. The history and physical examination during follow-up evaluations should be focused on the development of signs or symptoms of increased shunting. Echocardiography is indicated when there is concern that the shunt may be increasing, or to confirm spontaneous closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Which ASDs should be closed?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of isolated secundum ASDs &lt;6 mm diameter in infants close spontaneously by two years, and some as late as 5 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Thus, in the absence of associated symptoms, early closure is not indicated for these defects. Defects of moderate size (at least 6 to 8 mm in diameter) and larger are relatively unlikely to close spontaneously. However, closure of even moderate and large isolated secundum ASDs is not recommended in asymptomatic patients before 2 years of age due to the possibility, however small, of spontaneous closure. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The generally accepted clinical standard is to repair those isolated secundum ASDs with a large left-to-right shunt resulting in symptoms or significant right heart enlargement, usually associated with a ratio of pulmonary to systemic flow",
"    <span class=\"nowrap\">",
"     (Qp/Qs)",
"    </span>",
"    exceeding 2:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/9\">",
"     9",
"    </a>",
"    ]. The American Heart Association has recommended a threshold",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    &ge;1.5:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/10\">",
"     10",
"    </a>",
"    ], while the Canadian Cardiac Society recommended a threshold",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    &gt;2:1, or &gt;1.5:1 in the presence of reversible pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac catheterization has been considered the gold standard for",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    measurement for many years. However, pulsed Doppler echocardiography may be used for",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    measurement once the existence of an acceptable correlation between echocardiographic and catheterization laboratory estimates of shunt flow have been established for an individual laboratory. Because it is noninvasive, echocardiography more easily permits serial monitoring. Phase contrast magnetic resonance imaging is an excellent alternative standard for",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    measurement. For a review of the technical aspects of this measurement, see the following topic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=see_link&amp;anchor=H15#H15\">",
"     \"Identification and assessment of atrial septal defects in adults\", section on 'Estimation of shunt flow ratio and volume'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for closure of asymptomatic ASDs that are not associated with right heart enlargement and do not meet the",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    criteria are less clear. Evolving experience with transcatheter ASD closure may make a subset of such patients suitable candidates for closure. Since an increase in shunt volume can occur with moderate-sized ASDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/5\">",
"     5",
"    </a>",
"    ], periodic follow-up of patients with such defects is clearly indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Small ASDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;No large randomized trials have demonstrated a benefit of closure of small ASDs or PFOs in asymptomatic patients. Without the justification of such data, we do not advocate closure of such defects in the general population in the absence of symptoms.",
"   </p>",
"   <p>",
"    The risk of paradoxical embolism through a small ASD or valve-competent PFO is uncertain. The benefit of ASD closure in reducing the risk of embolism must be weighed against the short and long term risks of the procedure for closure. These procedure risks are changing as closure techniques continue to evolve. Closure is recommended by many physicians in patients with a small ASD or PFO who have experienced embolic strokes or transient ischemic attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closure is also controversial when pulmonary hypertension is present. However, pulmonary vascular disease is an uncommon complication of an isolated ASD, and when it occurs, the diagnosis is usually made in adulthood. The management of such patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to surgery, a comprehensive noninvasive evaluation is essential to exclude pulmonary hypertension and associated anatomic defects such as anomalous pulmonary and systemic venous connections. In nearly all cases, echocardiography can resolve these questions, obviating the need for cardiac catheterization.",
"   </p>",
"   <p>",
"    Surgical closure is usually performed using a patch of pericardium or Dacron. Small defects are often closed by direct suturing. However, suture closure of large defects can lead to distortion of the atrium. Cardiopulmonary bypass is required for the procedure. Repair of sinus venosus defects requires placement of a patch to direct the right pulmonary venous return into the left atrium and the systemic venous return into the right atrium.",
"   </p>",
"   <p>",
"    Intraoperative transesophageal echocardiography (TEE) can assess the adequacy of repair and detect residual flow across the surgical site (",
"    <a class=\"graphic graphic_movie graphicRef54350 \" href=\"mobipreview.htm?40/32/41487\">",
"     movie 1",
"    </a>",
"    ). TEE can also detect tricuspid or mitral regurgitation, either of which may occur if tension from the repair on the valvular annulus distorts the geometry of leaflet coaptation.",
"   </p>",
"   <p>",
"    The outcome of surgery is usually good, although up to one-fourth of patients have postoperative complications. This was illustrated by a series of 87 children in Australia, ages two months to 15 years, who had surgical closures of secundum ASDs from 1995 to 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/14\">",
"     14",
"    </a>",
"    ]. The following complications were noted; more than one occurred in some patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pericardial effusion requiring drainage &mdash; 10 patients",
"     </li>",
"     <li>",
"      Pleural effusions requiring drainage &mdash; 3 patients",
"     </li>",
"     <li>",
"      Pneumothorax requiring drainage &mdash; 2 patients",
"     </li>",
"     <li>",
"      Post-extubation stridor requiring treatment &mdash; 2 patients",
"     </li>",
"     <li>",
"      Arrhythmias that resolved spontaneously &mdash; 2 patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other less frequent complications included pneumonia, seizures, prolonged vomiting from ileus, and wound infection. No deaths occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transcatheter closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In December 2001, the US Food and Drug Administration (FDA) Center for Devices and Radiological Health approved the Amplatzer Septal Occluder (",
"    <a class=\"graphic graphic_figure graphicRef52160 \" href=\"mobipreview.htm?9/52/10050\">",
"     figure 2",
"    </a>",
"    ) and the Cardio-Seal Septal Occlusion System for percutaneous closure of secundum ASDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/15\">",
"     15",
"    </a>",
"    ]. In 2007, the FDA also approved the HELEX Septal Occluder for percutaneous closure of secundum ASDs, however this device is not suitable for defects greater than 18 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Sinus venosus defects, coronary sinus defects, primum ASDs, and complex congenital lesions require surgical correction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/62/36837?source=see_link\">",
"     \"Devices for percutaneous closure of a secundum atrial septal defect\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transcatheter closure avoids cardiopulmonary bypass, thoracotomy, and atriotomy and is associated with excellent outcomes. As a result, this approach has largely replaced surgery in some centers for the closure of small to moderate secundum ASDs that have appropriate anatomic characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ideal lesion for transcatheter closure is considered to be a secundum defect less than 20 mm in diameter. Larger secundum defects are generally closed surgically, although defects over 30 mm have been successfully closed by the catheter technique. Percutaneous closure also requires a rim of tissue around the defect of at least 5 mm to prevent obstruction of the coronary sinus, right pulmonary veins, vena cavae or atrioventricular valves. The insertion of more than one device to close multiple ASDs is safe and effective if the patient is large enough (ideally &gt;20 kg) and the distance between the defects is adequate (at least 7 mm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Echocardiographic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of transesophageal or intracardiac echocardiography may facilitate the deployment of transcatheter ASD closure devices. Measurement of the size and location of the ASD by transesophageal echocardiography (TEE) can help select the appropriate device. In addition, TEE can be used to guide the procedure in real time, an approach that may minimize fluoroscopy time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/20\">",
"     20",
"    </a>",
"    ]. Two- or even three-dimensional TEE is particularly helpful when multiple devices are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of intracardiac echocardiography (ICE) has provided a modality for evaluating cardiac anatomy that may be particularly well-suited for use in the management of ASDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. ICE can provide guidance for device placement and facilitates proper device selection by providing an accurate assessment of the size and shape (typically elliptical) of the defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ICE has the following advantages compared to TEE: it does not require endotracheal intubation or general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]; it permits continuous monitoring during the procedure; and it may shorten the duration of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110819457\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are associated with both closure approaches for ASDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110819850\">",
"    <span class=\"h3\">",
"     Surgical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard surgical technique for atrial defect closure requires sternotomy or thoracotomy, atriotomy, and the use of cardiopulmonary bypass, with its potentially deleterious consequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110819865\">",
"    <span class=\"h3\">",
"     Transcatheter complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprocedural complications associated with transcatheter closure of an ASD include device embolization or malposition, and arrhythmias (usually atrial but can include sudden death) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. The type and frequency of complications was evaluated in a report of 417 children and adults (mean age 27 &plusmn; 19 years) who underwent secundum ASD closure with the Amplatzer or Cardio-Seal device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/28\">",
"     28",
"    </a>",
"    ]. Complications during hospitalization occurred in 8.6 percent of patients. These included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A persistent shunt due to device embolization or malposition required surgery in 2.4 percent and was managed percutaneously in 1.0 percent. In another series of 124 patients, 6.5 percent required surgery for device malposition or embolization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atrial fibrillation or supraventricular tachycardia in 2.4 percent.",
"     </li>",
"     <li>",
"      Heart block, pericardial effusion, iliac vein dissection, or groin hematoma in 2.2 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other infrequent complications subsequent to catheter ASD occlusion include pericardial effusion, cardiac perforation, iliac vein dissection, groin hematoma at the puncture site, transient ST segment elevation, transient atrioventricular block, and transient ischemic attack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/26,28-30\">",
"     26,28-30",
"    </a>",
"    ]. With the Cardio-Seal device, protrusion of one arm through the defect and supporting arm fractures can occur, but do not typically produce complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late complications are unusual. In the above report of 417 patients, there was one case of peripheral embolization at one year, and one case of sudden cardiac death at 1.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/28\">",
"     28",
"    </a>",
"    ]. However, major late complications, including aortic perforation, have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/32\">",
"     32",
"    </a>",
"    ]. Although present experience suggests that such major late problems are quite rare, a completely definitive assessment of long term risk cannot currently be made, because device technology and implantation technique continue to change and because follow-up times are necessarily limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110819464\">",
"    <span class=\"h2\">",
"     Transcatheter closure versus surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited reports available suggest that the rates of procedural success may be comparable to or possibly better with surgery than with percutaneous transcatheter closure, but that the rate of complications and length of hospital stay may be reduced with the percutaneous approach.",
"   </p>",
"   <p>",
"    The two approaches were compared in multicenter nonrandomized study of 442 children and young adults undergoing percutaneous closure with the Amplatzer device (median age 9.8 years) and 154 undergoing surgery (median age 4.1 years); the choice of procedure was based upon the patients' choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/27\">",
"     27",
"    </a>",
"    ]. There were no deaths in either group. The rate of procedural success was significantly higher with surgery (100 versus 96 percent), while the transcatheter closure was associated with significant reductions in complication rate (7.2 versus 24.0 percent) and mean hospital stay (1.0 versus 3.4 days). At the 12 month follow-up of patients treated with the Amplatzer device, a residual shunt was present in 1.5 percent; one patient required a second procedure to correct a residual shunt at 24 month follow-up.",
"   </p>",
"   <p>",
"    Similar short-term outcomes were noted in another report comparing 61 patients who underwent surgical closure (median age 20 years) with 61 who underwent closure with an Amplatzer device (median age 12 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/34\">",
"     34",
"    </a>",
"    ]. Closure rates in the two groups were identical (98 percent); the mean hospital stay was shorter in the percutaneous closure group (three versus eight days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110819655\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with an ASD may have problems during pregnancy, including arrhythmias, thromboembolism, and bleeding. However, there is no available evidence to suggest that pregnant patients should be managed differently from nonpregnant patients with respect to the indications for ASD closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25610?source=see_link&amp;anchor=H19741008#H19741008\">",
"     \"Management of atrial septal defects in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Scuba diving and altitude exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with small ASDs who are treated medically may be at increased risk for complications when they experience high or low atmospheric pressure, as with scuba diving or high-altitude climbing. Scuba diving in patients with an ASD has been associated with increased risks of decompression illness and paradoxical emboli, while high-altitude exposure has been associated with risk of increased right-to-left shunting and oxygen desaturation. Among patients with an ASD (or other intracardiac shunt), scuba diving is generally contraindicated, while consultation with a cardiologist specializing in congenital defects is recommended before high altitude exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4633?source=see_link&amp;anchor=H24#H24\">",
"     \"Complications of scuba diving\", section on 'Cardiovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16042?source=see_link&amp;anchor=H15#H15\">",
"     \"High altitude, air travel, and heart disease\", section on 'Congenital heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival rate of children with ASD is excellent. This was illustrated by the United Kingdom Northern Congenital Abnormality survey of children born between 1985 and 2003 that reported a 20-year estimated survival rate of 96.3 for children diagnosed with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The short- and long-term outcomes are generally excellent after either surgical or transcatheter closure of an isolated ASD in children. The potential concerns associated with a persistent small ASD are described above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Small ASDs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is almost no increase in long-term mortality or serious morbidity, compared to controls, following surgical repair of an ASD in childhood, as illustrated by the following observations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The natural history of surgical correction of ASDs was evaluated in all 123 patients with isolated secundum or sinus venosus defects who underwent surgery at the Mayo Clinic between 1956 and 1960 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/38\">",
"       38",
"      </a>",
"      ]. Actuarial 27-year survival rates in patients in whom surgery was performed at &le;11 years or at 12 to 24 years of age were similar to those of controls matched for age and sex (97 and 93 percent, respectively). In contrast, 27-year survival rates compared to matched controls were significantly lower when surgery was performed at 25 to 41 years of age (84 versus 91 percent), and after age 41 (40 versus 59 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An excellent long-term prognosis when surgical repair of an ASD is performed in childhood was also noted in a series of 135 children in which there was no cardiovascular mortality, stroke, heart failure, or pulmonary hypertension 21 to 33 years after repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/39\">",
"     39",
"    </a>",
"    ]. Symptomatic supraventricular tachyarrhythmias were present in 6 percent of patients at 15 years, and in an additional 2 percent in the next decade, a lower rate than in untreated ASDs or after surgical correction in adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Transcatheter closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term (less than one year) outcomes of transcatheter closure have been excellent with reported procedural success rates of 88 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/17,26,27,34,40\">",
"     17,26,27,34,40",
"    </a>",
"    ]. In one series of 100 children and young adults (mean age 13 years), the Amplatzer device was successfully implanted in 93 with a procedure time ranging from 30 to 180 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/26\">",
"     26",
"    </a>",
"    ]. The total ASD occlusion rate at three months was 99 percent.",
"   </p>",
"   <p>",
"    Although clinical indications for ASD closure are less commonly encountered in infancy, the Amplatzer device has also been used in this age group. In a single case series, successful closure was reported in 14 of 15 infants 0.5 to 11.9 months of age with a weight range from 3.0 to 8.3 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/41\">",
"     41",
"    </a>",
"    ]. Devices were placed either percutaneously (n = 11) or by hybrid surgical approach (n = 3). At one-year follow-up, complete closure was seen in 14 infants, with one death due to progressive pulmonary hypertension occurring weeks after the procedure. Complications included thrombosis of the inferior vena cava due to vascular intimal injury in one patient, and minor complications of transient arrhythmias (n = 2) and the need for blood transfusion (n = 1).",
"   </p>",
"   <p>",
"    These outcomes with the Amplatzer device persist at long-term follow-up. This was illustrated in a review of 151 children and young adults (mean age 11.9 years) who underwent successful closure and were then followed for a median of 78 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/42\">",
"     42",
"    </a>",
"    ]. There were no deaths or significant complications and all defects were completely closed at three years and remained closed thereafter.",
"   </p>",
"   <p>",
"    An initial experience with the Cardio-Seal device involved 50 patients (median age 9.7 years); 22 percent had multiple ASDs and 38 percent had a deficient rim of atrial tissue (&lt;4 mm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/31\">",
"     31",
"    </a>",
"    ]. At a mean follow-up of 9.9 months, all patients were asymptomatic. A small residual shunt was present in 46 percent of patients without evidence of hemodynamic consequences.",
"   </p>",
"   <p>",
"    In a study that included 33 deployments of the HELEX device in children (age range 13 to 220 months), four small residual shunts were noted at a mean of 63 months after implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/40\">",
"     40",
"    </a>",
"    ]. No deaths or long-term complications occurred. Data from clinical trials demonstrate that the HELEX device appears to be best suited for small to moderate secundum ASDs (stretch diameter &lt;20 mm) with reported success rates of about 98 percent at one-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/17\">",
"     17",
"    </a>",
"    ]. Device wire frame fracture occurred in 8 percent of deployments but only one patient required treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38936/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more complete discussion on the different available devices for ASD closure is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/62/36837?source=see_link\">",
"     \"Devices for percutaneous closure of a secundum atrial septal defect\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 guidelines of the American Heart Association (AHA) recommend",
"    <strong>",
"     no",
"    </strong>",
"    antibiotic prophylaxis in children with an isolated ASD, except in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children with a repaired ASD, which required the use of prosthetic material or device, prophylactic antibiotics are recommended for dental and respiratory tract procedures during the first six months after the repair.",
"     </li>",
"     <li>",
"      In children with repaired ASD with a residual defect at the site or adjacent to the site of a prosthetic device, antibiotic prophylaxis is recommended for dental and respiratory tract procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These updated guidelines",
"    <strong>",
"     no",
"    </strong>",
"    longer include associated mitral regurgitation as an indication for antibiotic prophylaxis. Prophylaxis is no longer recommended for gastrointestinal or genitourinary tract procedures.",
"   </p>",
"   <p>",
"    The 2007 AHA guidelines are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/31/6642?source=see_link\">",
"       \"Patient information: Atrial septal defect (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110819233\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital defects of the atrial septum are common, vary in size and anatomic location, and are either isolated or associated with other cardiac anomalies. The management of an atrial septal defect (ASD) is dependent upon its likely natural course and the presence of significant clinical manifestations and symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secundum ASDs can close spontaneously, remain unchanged, or enlarge. Spontaneous closure, or a decrease in size, is most likely to occur in defects less than 7 to 8 mm in diameter and with patients who are younger in age at the time of diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with moderate to large ASDs, left-to-right shunting increases with age if the defect is not corrected. Most patients with defects of this size become symptomatic before 40 years of age and may result in heart failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progressive pulmonary hypertension in older patients. &nbsp;",
"     </li>",
"     <li>",
"      The treatment for isolated secundum ASD is closure of the defect, which can be achieved by a surgical or percutaneous transcatheter approach. The generally accepted clinical standard for repair is an isolated secundum ASDs with a large left-to-right shunt resulting in symptoms or significant right heart enlargement. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Which ASDs should be closed?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical closure is usually performed using a patch of pericardium or Dacron. Prior to surgery, a comprehensive noninvasive evaluation is essential to exclude pulmonary hypertension and associated anatomic defects such as anomalous pulmonary and systemic venous connections. In nearly all cases, echocardiography can resolve these questions, obviating the need for cardiac catheterization. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transcatheter closure avoids cardiopulmonary bypass, thoracotomy, and atriotomy, and is associated with excellent outcomes. As a result, this approach has largely replaced surgery in many centers for patients with a defect that is less than 20 mm in diameter. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Transcatheter closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcome of patients with ASD is excellent with 20-year survival rates of over 96 percent and minimal serious adverse effects after either surgical or transcatheter closure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited data suggest that the rates of procedural success may be comparable or possibly better with surgery than with percutaneous transcatheter closure, but that the rate of complications and length of hospital stay is reduced with the percutaneous approach. As a result, the choice of procedure should be based on the expertise of the center and the preferences of the patient and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      family. (See",
"      <a class=\"local\" href=\"#H110819464\">",
"       'Transcatheter closure versus surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend prophylactic antibiotics for dental procedures be given to patients with an isolated ASD except for dental and respiratory tract procedures during the first six months after the repair in patients in whom prosthetic material or device is used, or in patients, in whom there is a residual defect at or adjacent to the site of a prosthetic device. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Endocarditis prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/1\">",
"      Feldt RH, Avasthey P, Yoshimasu F, et al. Incidence of congenital heart disease in children born to residents of Olmsted County, Minnesota, 1950-1969. Mayo Clin Proc 1971; 46:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/2\">",
"      Radzik D, Davignon A, van Doesburg N, et al. Predictive factors for spontaneous closure of atrial septal defects diagnosed in the first 3 months of life. J Am Coll Cardiol 1993; 22:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/3\">",
"      Hanslik A, Pospisil U, Salzer-Muhar U, et al. Predictors of spontaneous closure of isolated secundum atrial septal defect in children: a longitudinal study. Pediatrics 2006; 118:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/4\">",
"      Helgason H, Jonsdottir G. Spontaneous closure of atrial septal defects. Pediatr Cardiol 1999; 20:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/5\">",
"      McMahon CJ, Feltes TF, Fraley JK, et al. Natural history of growth of secundum atrial septal defects and implications for transcatheter closure. Heart 2002; 87:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/6\">",
"      Brassard M, Fouron JC, van Doesburg NH, et al. Outcome of children with atrial septal defect considered too small for surgical closure. Am J Cardiol 1999; 83:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/7\">",
"      Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 2002; 20:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/8\">",
"      Goetschmann S, Dibernardo S, Steinmann H, et al. Frequency of severe pulmonary hypertension complicating \"isolated\" atrial septal defect in infancy. Am J Cardiol 2008; 102:340.",
"     </a>",
"    </li>",
"    <li>",
"     Vick GW III. Defects of the atrial septum Including atrioventricular septal defects. In: Science and Practice of Pediatric Cardiology, 2nd, Garson A Jr, Bricker JT, Fisher DJ, Neish SR (Eds), Williams &amp; Wilkins, Baltimore 1998. p.1141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/10\">",
"      Driscoll D, Allen HD, Atkins DL, et al. Guidelines for evaluation and management of common congenital cardiac problems in infants, children, and adolescents. A statement for healthcare professionals from the Committee on Congenital Cardiac Defects of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994; 90:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/11\">",
"      Therrien J, Dore A, Gersony W, et al. CCS Consensus Conference 2001 update: recommendations for the management of adults with congenital heart disease. Part I. Can J Cardiol 2001; 17:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/12\">",
"      Windecker S, Meier B. Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale and cryptogenic stroke: to close or not to close? Closure: what else! Circulation 2008; 118:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/13\">",
"      Mess&eacute; SR, Kasner SE. Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale in cryptogenic stroke: not to close. Circulation 2008; 118:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/14\">",
"      Jones DA, Radford DJ, Pohlner PG. Outcome following surgical closure of secundum atrial septal defect. J Paediatr Child Health 2001; 37:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/15\">",
"      Schwetz BA. From the Food and Drug Administration. JAMA 2002; 287:578.",
"     </a>",
"    </li>",
"    <li>",
"     Delaney JW, Chan KC and Rhodes JF Jr. The design and deployment of the HELEX septal occluder. Congenit Heart Dis 2006: 1(5):202.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/17\">",
"      Latson LA, Jones TK, Jacobson J, et al. Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder. Am Heart J 2006; 151:1129.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/18\">",
"      Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation 2003; 107:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/19\">",
"      Cao Q, Radtke W, Berger F, et al. Transcatheter closure of multiple atrial septal defects. Initial results and value of two- and three-dimensional transoesophageal echocardiography. Eur Heart J 2000; 21:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/20\">",
"      Ewert P, Berger F, Daehnert I, et al. Transcatheter closure of atrial septal defects without fluoroscopy: feasibility of a new method. Circulation 2000; 101:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/21\">",
"      Earing MG, Cabalka AK, Seward JB, et al. Intracardiac echocardiographic guidance during transcatheter device closure of atrial septal defect and patent foramen ovale. Mayo Clin Proc 2004; 79:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/22\">",
"      Bartel T, Konorza T, Arjumand J, et al. Intracardiac echocardiography is superior to conventional monitoring for guiding device closure of interatrial communications. Circulation 2003; 107:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/23\">",
"      Zanchetta M, Onorato E, Rigatelli G, et al. Intracardiac echocardiography-guided transcatheter closure of secundum atrial septal defect: a new efficient device selection method. J Am Coll Cardiol 2003; 42:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/24\">",
"      Mullen MJ, Dias BF, Walker F, et al. Intracardiac echocardiography guided device closure of atrial septal defects. J Am Coll Cardiol 2003; 41:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/25\">",
"      Boccalandro F, Baptista E, Muench A, et al. Comparison of intracardiac echocardiography versus transesophageal echocardiography guidance for percutaneous transcatheter closure of atrial septal defect. Am J Cardiol 2004; 93:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/26\">",
"      Chan KC, Godman MJ, Walsh K, et al. Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience. Heart 1999; 82:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/27\">",
"      Du ZD, Hijazi ZM, Kleinman CS, et al. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol 2002; 39:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/28\">",
"      Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol 2002; 39:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/29\">",
"      Berdat PA, Chatterjee T, Pfammatter JP, et al. Surgical management of complications after transcatheter closure of an atrial septal defect or patent foramen ovale. J Thorac Cardiovasc Surg 2000; 120:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/30\">",
"      Maimon MS, Ratnapalan S, Do A, et al. Cardiac perforation 6 weeks after percutaneous atrial septal defect repair using an Amplatzer septal occluder. Pediatrics 2006; 118:e1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/31\">",
"      Pedra CA, Pihkala J, Lee KJ, et al. Transcatheter closure of atrial septal defects using the Cardio-Seal implant. Heart 2000; 84:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/32\">",
"      Divekar A, Gaamangwe T, Shaikh N, et al. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol 2005; 45:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/33\">",
"      McElhinney DB. Patent foramen ovale closure: let's keep the heart in mind. Circulation 2009; 119:2967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/34\">",
"      Berger F, Vogel M, Alexi-Meskishvili V, Lange PE. Comparison of results and complications of surgical and Amplatzer device closure of atrial septal defects. J Thorac Cardiovasc Surg 1999; 118:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/35\">",
"      Landzberg MJ. Closure of atrial septal defects in adult patients: justification of the \"tipping point\". J Interv Cardiol 2001; 14:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/36\">",
"      Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001; 38:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/37\">",
"      Tennant PW, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. Lancet 2010; 375:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/38\">",
"      Murphy JG, Gersh BJ, McGoon MD, et al. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med 1990; 323:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/39\">",
"      Roos-Hesselink JW, Meijboom FJ, Spitaels SE, et al. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years. Eur Heart J 2003; 24:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/40\">",
"      Silverstein MD, Qin H, Mercer SQ, et al. Risk factors for 30-day hospital readmission in patients &ge;65 years of age. Proc (Bayl Univ Med Cent) 2008; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/41\">",
"      Diab KA, Cao QL, Bacha EA, Hijazi ZM. Device closure of atrial septal defects with the Amplatzer septal occluder: safety and outcome in infants. J Thorac Cardiovasc Surg 2007; 134:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38936/abstract/42\">",
"      Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders. J Am Coll Cardiol 2005; 45:505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5779 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38936=[""].join("\n");
var outline_f38_1_38936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H110819233\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Which ASDs should be closed?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Small ASDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transcatheter closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Echocardiographic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110819457\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110819850\">",
"      - Surgical complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110819865\">",
"      - Transcatheter complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110819464\">",
"      Transcatheter closure versus surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110819655\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Scuba diving and altitude exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Transcatheter closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ENDOCARDITIS PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110819233\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5779|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/36/7748\" title=\"figure 1\">",
"      Atrial septal defect anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/52/10050\" title=\"figure 2\">",
"      Amplatzer septal occluder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5779|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?40/32/41487\" title=\"movie 1\">",
"      TTE with color Doppler post-ASD repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/62/36837?source=related_link\">",
"      Devices for percutaneous closure of a secundum atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16042?source=related_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=related_link\">",
"      Identification and assessment of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25610?source=related_link\">",
"      Management of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/31/6642?source=related_link\">",
"      Patient information: Atrial septal defect (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14328?source=related_link\">",
"      Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_1_38937="Routine comprehensive care for children with sickle cell disease";
var content_f38_1_38937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Routine comprehensive care for children with sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38937/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38937/contributors\">",
"     Zora R Rogers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38937/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38937/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/1/38937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/1/38937/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/1/38937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H112753056\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remarkable progress in the care of children with sickle cell disease (SCD) over the past several decades is directly attributable to the evolution of a standard of anticipatory guidance offered to families of affected children by most pediatric hematologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/1\">",
"     1",
"    </a>",
"    ]. Although there is a paucity of formal evidence-based standards of care, the National Institutes of Health (NIH) have convened an expert panel to develop evidence-based guidelines to supplement their decade-old monograph that has been the standard for SCD care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/2\">",
"     2",
"    </a>",
"    ]. This topic review represents a synthesis of the standards promoted by various professional societies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], by state and regional guideline efforts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/6\">",
"     6",
"    </a>",
"    ], and by more recent attempts to define quality care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each location at which clinical care is provided to children with SCD will have a different approach of how to implement the policies and patient education goals outlined below. Many providers use a roadmap or outline of care that is signed off at each visit or when a milestone is reached. In addition, formal assessment of these elements of care may serve as the basis for a quality improvement project [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. However it is executed, it is beneficial to develop an outline of care that can be used to verify that planned educational and screening maneuvers have occurred.",
"   </p>",
"   <p>",
"    The key elements of routine care and anticipatory guidance for a child with SCD are outlined here. Overviews of other aspects of the evaluation and management of SCD are discussed in separate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=see_link\">",
"       \"Diagnosis of sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"       \"Overview of the clinical manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"       \"Overview of the management of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=see_link\">",
"       \"Management of fever in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed discussion of specific complications, such as acute chest syndrome, painful crises, and cerebrovascular events, can be accessed through these overview topics or through a specific search of the UpToDate database.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112753063\">",
"    <span class=\"h1\">",
"     NEWBORN SCREENING FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of universal newborn screening for hemoglobinopathies in the United States and the United Kingdom offers the unparalleled opportunity to identify",
"    <strong>",
"     ALL",
"    </strong>",
"    children with clinically significant sickle cell diseases (SCD) in the newborn period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112753070\">",
"    <span class=\"h2\">",
"     First visit with a sickle cell disease clinician",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with SCD should be promptly referred for consultation with clinicians experienced in SCD. The SCD clinician or team will provide SCD-specific anticipatory guidance about common early childhood issues, will teach the family to evaluate for complications that require urgent treatment, will develop strategies to provide requisite urgent care when complications do arise, and will determine the necessity for prophylactic penicillin. Depending upon local resources, the SCD clinician may be a pediatric hematologist (often within a specialized SCD program) or may be a knowledgeable general pediatrician or family physician. The following are essential elements of the first visit with an experienced SCD clinician:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112753078\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of the first visit with the experienced SCD clinician depends upon the hemoglobinopathy. For patients with hemoglobin SS (HbSS) or hemoglobin S-&beta;",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia (HbS-&beta;",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia), the first visit should be before eight weeks of age. For those with hemoglobin SC (HbSC), hemoglobin S-&beta;",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia (HbS-&beta;",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia), and other sickle cell syndromes, the first visit can be delayed until 12 to 16 weeks of age, if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112753085\">",
"    <span class=\"h3\">",
"     Laboratory testing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Confirmation of exact diagnosis",
"      </strong>",
"      &mdash; The confirmation of an exact diagnosis will depend upon the newborn screening program&rsquo;s services. At least two separate blood tests, including the immediate newborn sample, should be used to confirm that this child is the one with the abnormal hemoglobin. Confirmatory testing is performed using hemoglobin electrophoresis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a deoxyribonucleic acid (DNA)-based test to confirm the type of SCD. As an example, a DNA-based test may be required to distinguish between the &ldquo;FS&rdquo; pattern seen on electrophoresis in the newborn with either HbSS or HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=see_link\">",
"       \"Diagnosis of sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Complete blood count and reticulocyte count",
"      </strong>",
"      &mdash; A complete blood count, with reticulocyte count, should be performed at the first visit and at each subsequent visit to establish baseline values for the individual patient. The results should be interpreted in view of the physiologic decline of hemoglobin in infants, with a nadir between six to nine weeks of age. Premature infants may have an earlier and more profound physiologic anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20572891\">",
"    <span class=\"h3\">",
"     Medication",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prescription of prophylactic penicillin",
"      </strong>",
"      &mdash; Penicillin VK (125 mg twice daily) should be prescribed for all children diagnosed with HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. Other sickle cell syndromes may not require this prophylaxis due to the lower risk of functional asplenia or onset at a later age. Liquid penicillin will need to be refilled every 14 days, which can be inconvenient and costly for the family. Therefore, some clinicians suggest using half of a penicillin VK 250 mg tablet, dissolved in a small amount of formula. Penicillin prophylaxis is generally continued until the child has completed the immunization series with the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23), after five years of age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the management of sickle cell disease\", section on 'Prophylactic penicillin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=see_link&amp;anchor=H15#H15\">",
"       \"Management of fever in sickle cell disease\", section on 'Management in variant sickle cell syndromes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"       Folic acid",
"      </a>",
"      &mdash; Although 400 mcg to 1 mg daily is often recommended for children with HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia, there are no convincing data that this is required. Formula-fed infants in particular receive adequate folic acid in their diet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20572848\">",
"    <span class=\"h3\">",
"     Education and anticipatory guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education of the child&rsquo;s parents or caregivers about the routine and emergency complications of SCD is a cornerstone of effective medical care. Each of the following areas should be covered in the initial visit and should also be reviewed during each follow-up visit to reinforce the information and to ensure understanding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8865000\">",
"    <span class=\"h4\">",
"     Inheritance pattern and genetic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should inform the parents that they each carry an abnormal hemoglobin gene, and that there is a 25 percent recurrence risk of another child with SCD for the couple with each pregnancy. Each parent should be encouraged to share the information about their trait status with any subsequent partner, so that all couples will know if there is the risk of an affected child with any subsequent pregnancy and will be able to make an informed decision about whether to take on this risk before another child is conceived. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13960?source=see_link\">",
"     \"Sickle cell trait\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8865008\">",
"    <span class=\"h4\">",
"     Splenic palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The family should be educated about the risk of splenic enlargement, termed splenic sequestration, which may lead acutely to severe life-threatening anemia. Eventually, because of infarction, this process may lead to splenic hypofunction and to functional asplenia, placing the child at risk for overwhelming infection with encapsulated organisms. The risk for acute splenic sequestration crisis is highest in infants and young children (up to age three years) with HbSS or HbS-&beta;",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia. Children with HbSC also develop splenic sequestration, but typically this occurs at an older age and usually is not an acute clinical problem because of the higher baseline hemoglobin in HbSC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Splenic sequestration crisis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H12679833#H12679833\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Reduced or absent splenic function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The family should be taught to palpate the spleen at least daily when the child is well and more often when the child is ill. If the spleen is felt to be enlarged by the parent, the child should be examined by a clinician to confirm enlargement of the spleen, and a blood count should be obtained and compared with the steady state value to determine if transfusion is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8865016\">",
"    <span class=\"h4\">",
"     Fever plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;All caregivers should be educated that a fever over 101.5&deg;F (38.5&deg;C) requires urgent medical attention, even if the fever immediately comes down with or without antipyretics. The exact degree of fever elevation may be based upon the patient&rsquo;s age and clinical characteristics, as well as local preference. However, generally, a temperature between 101&deg;F and 102&deg;F (38&deg;C and 39&deg;C) is selected, and a medical evaluation is recommended within four hours after fever onset. A specific plan should be made for where the family should bring the child with SCD when he or she develops a fever, in consultation with the primary care physician. Options include the primary care physician&rsquo;s office, a local emergency department (ED), or a tertiary pediatric hospital ED or clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=see_link\">",
"     \"Management of fever in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8865024\">",
"    <span class=\"h4\">",
"     How to contact the sickle cell specialist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expert care should be available to the family of a child with SCD whenever needed. Contact information should be provided in writing to the family, for use when calling with follow-up questions or with new problems or when a complication such as fever develops that requires urgent medical evaluation. At a minimum, the family should be given contact information to allow for after-hours telephone consultation by generalist practitioners and emergency physicians who are seeing the patient when they are having a problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112753092\">",
"    <span class=\"h1\">",
"     ADDITIONAL EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following issues may be introduced during the first visit. However, detailed discussion may be delayed until later in the first year, to avoid overwhelming parents and caregivers at the first visit. Once introduced, these issues should be reviewed and reinforced at each subsequent follow-up visit.",
"   </p>",
"   <p>",
"    In particular, the caregivers must have a clear understanding of symptoms requiring urgent evaluation, and they must have an action plan (",
"    <a class=\"graphic graphic_table graphicRef86907 \" href=\"mobipreview.htm?31/36/32331\">",
"     table 1",
"    </a>",
"    ). These medical issues can be introduced gradually, as appropriate to the child&rsquo;s age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20573400\">",
"    <span class=\"h2\">",
"     Painful crises or events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parents or caretakers should be educated about management of painful crises before the infant is four or five months old. Pain is the hallmark and the most feared complication in all forms of sickle cell disease (SCD). Discussions should emphasize that pain should be recognized and treated promptly, and this point should be reiterated at subsequent visits. Specifically, teaching should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Recognition of pain",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early symptoms of a painful crisis in a young child often include decreased activity (or lying quietly). Symmetric or asymmetric swelling may develop in the dorsum of the hands or feet, also called dactylitis or hand-foot syndrome. The pain may not be accompanied by crying.",
"     </li>",
"     <li>",
"      The school-aged child in the early stages of a painful crisis either may be uninterested in usual activities or may try to ignore the pain. If the pain is not recognized and treated, it may progress to overwhelming pain which is difficult to control. Therefore, the child should be encouraged to tell a trusted adult when he or she feels pain. The adult should be aware of the need for early treatment and should be educated about the different methods available to treat pain.",
"     </li>",
"     <li>",
"      Older children and adolescents will experience pain in many ways. During office visits, the child should be engaged in discussing how to avoid triggers for their pain and how they can manage their pain at home.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Management of pain",
"      </strong>",
"      &mdash; Details of pain management are discussed in separate topic reviews. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=see_link\">",
"       \"Acute pain management in adults with sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link\">",
"       \"Evaluation and management of pain in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Key points to communicate to the parents or caretakers are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nonpharmacologic measures should be used in addition to pharmacologic treatments of pain. These include distraction, reading or being read to, soft music, or other activities to induce relaxation.",
"     </li>",
"     <li>",
"      Fluids by mouth should be increased to twice maintenance volumes. The clinician should calculate this volume and should communicate the target volume to the family.",
"     </li>",
"     <li>",
"      Avoid being chilled. Encourage a shower or brief bath; massage or rub the affected area, as tolerated.",
"     </li>",
"     <li>",
"      Mild pain in young children may be managed with oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      in therapeutic doses (usually 10",
"      <span class=\"nowrap\">",
"       mg/kg/dose",
"      </span>",
"      every four hours) as needed.",
"     </li>",
"     <li>",
"      For moderate pain, oral opioids (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32230?source=see_link\">",
"       codeine",
"      </a>",
"      [1",
"      <span class=\"nowrap\">",
"       mg/kg/dose",
"      </span>",
"      of the codeine component] every four hours is the usual starting dose, escalating to higher doses of codeine, hydrocodone, or equivalent). This oral opioid can be alternated with the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , so that some medication can be given every two hours. Medications and doses should be discussed in advance of need, and the family should be prescribed medication at scheduled visits to have at home, to be used for treatment of subsequent painful events.",
"     </li>",
"     <li>",
"      The caretakers should be informed that constipation is a common side effect of effective pain medication (opioid and nonsteroidal antiinflammatory drugs [NSAID]), and the clinician should develop a plan for management.",
"     </li>",
"     <li>",
"      If the home measures described above do not relieve the pain enough to allow the child to rest, the child should present for urgent medical evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20573412\">",
"    <span class=\"h2\">",
"     Acute chest syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parents or caretakers should be educated about acute chest syndrome before the infant is six to nine months old. Families should be warned that acute chest syndrome is a peculiar complication of SCD that resembles pneumonia in another child. It may progress quickly, may result in involvement of multiple blood pulmonary blood vessels and airspaces, and can be life-threatening throughout the lifespan. They should be aware that it usually requires inpatient observation and parenteral antibiotics at least for initial management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key points to communicate to the family include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any shortness of breath or trouble breathing should result in an emergency room visit, just like with fever.",
"     </li>",
"     <li>",
"      Asthma is both a promoter and consequence of acute chest syndrome episodes. Therefore, it is essential to promptly recognize and to vigorously manage any asthma symptoms, including diligent use of preventer medications when indicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. A plan should be made for ongoing management of asthma either by the primary care physician or by an asthma specialist.",
"     </li>",
"     <li>",
"      Exposure to environmental tobacco smoke increases risks for asthma and acute chest syndrome. All household members that smoke should be strongly encouraged to quit and should be guided to smoking cessation resources. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of acute chest syndrome is presented in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"     \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20573429\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants with HbSS or HbS-&beta;",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia, the parents or caretakers should be educated about stroke risk before the infant is nine months old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key points to communicate to the family include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 1 in 10 children with HbSS disease experience thrombotic stroke by age 18. Warning signs of stroke include not moving a side of the face, arm, or leg, in the absence of pain. These stroke symptoms are observed in all age groups starting in early infancy. In adolescents, signs of hemorrhagic stroke include a severe headache.",
"     </li>",
"     <li>",
"      Transcranial Doppler (TCD) is an important method to screen for stroke risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/16\">",
"       16",
"      </a>",
"      ]. Elevated TCD velocities identify children at higher than standard risk. Persistently elevated TCD velocities indicate the need for interventions to prevent stroke, such as chronic transfusion. The first TCD examination should be scheduled soon after the child&rsquo;s second birthday.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of stroke in SCD is presented in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link\">",
"     \"Cerebrovascular complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20573439\">",
"    <span class=\"h2\">",
"     Priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;For male patients, the parents or caretakers should be educated about priapism before the infant is five years old (and ideally earlier). This is particularly important in boys with HbSS and HbS-&beta;",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia. Up to 80 percent of males with sickle cell anemia will experience priapism by age 18, and prolonged priapism (erection lasting longer than four hours) has been reported before five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=see_link\">",
"     \"Diagnosis and management of priapism in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Key points to communicate to the family include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Priapism is a painful erection. Like other painful events in SCD, it is caused by sickled cells.",
"     </li>",
"     <li>",
"      There are two patterns of priapism:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stuttering &mdash; These are brief episodes of priapism that may occur daily. Stuttering priapism and its management strategies can be addressed during regularly scheduled visits with the SCD clinician.",
"     </li>",
"     <li>",
"      Prolonged &mdash; These are episodes of priapism lasting over four hours, and they may result in penile ischemia and in permanent damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/18\">",
"       18",
"      </a>",
"      ]. A patient with an episode of prolonged priapism should seek immediate medical attention to minimize the chance of permanent vascular damage to the penis, which may lead to impotence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20573460\">",
"    <span class=\"h2\">",
"     Hydroxyurea, chronic transfusion, and stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;These three therapies are important options for all individuals with SCD. They should be discussed with",
"    <strong>",
"     every",
"    </strong>",
"    family and patient at appropriate times in the disease course. A synopsis of current thinking follows.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/53/25431?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      &mdash; This oral chemotherapy medication, when given chronically in low doses, will decrease the frequency and severity of painful events and of acute chest syndrome episodes, and it may perhaps reduce the risk of organ damage caused by SCD. The results of two studies (HUSOFT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/20\">",
"       20",
"      </a>",
"      ] and BABY HUG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/21\">",
"       21",
"      </a>",
"      ]) suggest that hydroxyurea may be given safely to children as young as eight months of age, although it is not approved by the United States Food and Drug Administration (FDA) for this age group. The benefits of hydroxyurea do not continue after the medication is stopped. Since the risk-to-benefit ratio of hydroxyurea or related decision-making may change as the child grows, its use should be discussed in early childhood, throughout the school years, and in adolescence and adulthood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"       \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic transfusion &mdash; Chronic transfusion consists of transfusion of packed red blood cells (PRBC) monthly (or at least 8 to 10 times a year), with a goal of reducing and maintaining the percentage of sickle hemoglobin to below 30 percent. This treatment decreases sickle cell complications; it is the strategy used to decrease the likelihood of primary and recurrent stroke. A major limitation of this therapy is iron overload, which requires chelation to prevent organ damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stem cell transplantation &mdash; Stem cell transplantation (also known as hematopoietic cell transplantation [HCT]) is a curative treatment for SCD that has been available since the 1990s. However, the risk of death and sterility from the procedure has limited its use. At the present time, stem cell transplantation from a sibling donor of either bone marrow or cord blood is a standard therapy available to cure SCD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"       \"Hematopoietic cell transplantation in sickle cell disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For children that do not have an HLA-matched sibling available as a donor, the risks of stem cell transplantation are considerably higher, and the likelihood of successful engraftment is lower. Unrelated donor bone marrow transplantation is under active research investigation. Unrelated donor cord blood transplantation has rarely been successful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112753099\">",
"    <span class=\"h1\">",
"     FOLLOW-UP VISITS WITH A SICKLE CELL DISEASE EXPERT CLINICIAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal interval of follow-up with an experienced sickle cell disease (SCD) clinician is an individualized decision based upon SCD type, family needs, other medical conditions, distance from expert care, and insurance requirements. However, we suggest a minimum of a 20- to 30-minute visit at the intervals indicated below, reserved for anticipatory guidance concerning issues specific to SCD and for verification of disease-specific immunization needs. This series of visits should be",
"    <strong>",
"     in addition",
"    </strong>",
"    to those needed for general pediatric primary care.",
"   </p>",
"   <p>",
"    If primary care is provided outside of the specialized SCD program, the SCD specialist should administer or inform the family and primary care provider about disease-specific vaccine requirements, which are outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112753106\">",
"    <span class=\"h2\">",
"     Routine monitoring at all visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are essential elements of all visits to the SCD clinician:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A",
"      <strong>",
"       complete blood count and reticulocyte count",
"      </strong>",
"      should be done at each SCD-specific visit (at a minimum annually), and a copy of the results should be given to the family. The family should be asked to bring this information if the child presents to an outside institution for an acute problem (eg, a crisis), for comparison.",
"     </li>",
"     <li>",
"      <strong>",
"       Height, weight, and head circumference",
"      </strong>",
"      should be measured, plotted on growth curves, and compared with prior values. Some decrement of growth often occurs between 6 and 24 months of age, corresponding to the decline in hemoglobin associated with increased beta chain synthesis. However, the subsequent rate of growth should be normal. This growth velocity data will be vital in assessment of pubertal delays or of short stature and in related treatment decisions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vital signs including",
"      <strong>",
"       blood pressure",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/25\">",
"       25",
"      </a>",
"      ] should be measured at each visit. Because of the high rate of idiopathic hypertension in the African-American community, increasing attention has been placed on the diagnosis and management of elevated blood pressures in childhood. Hypertension noted during painful crisis is attributed to the pain. However, careful review of blood pressure values measured during routine visits will provide early clues about hypertension, especially since the lower hemoglobin values in most patients with SCD should result in blood pressures that are lower than expected for age.",
"     </li>",
"     <li>",
"      Room air",
"      <strong>",
"       oxygen saturation",
"      </strong>",
"      should be recorded at least annually, using a transcutaneous oxygen (TcO2) sensor. TcO2 saturations are generally lower in children with SCD compared with healthy children. Therefore, it is important to have serial measurements of each child&rsquo;s baseline value when healthy, to be used for comparison when the child presents with an acute issue, such as a painful crisis or possible acute chest syndrome.",
"     </li>",
"     <li>",
"      Extended",
"      <strong>",
"       red blood cell antigen typing",
"      </strong>",
"      , at least for the Rh complex (CcDEe) and Kell antigens, should be considered in all patients with HbSS disease at a clinic visit in early childhood, in anticipation of a high likelihood of transfusion during childhood. Alternatively, some institutions offer strategies to perform this typing rapidly when transfusion is needed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8864157\">",
"    <span class=\"h2\">",
"     Additional age-specific tasks",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112754720\">",
"    <span class=\"h3\">",
"     Zero to two years",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intervals for visits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia: Every three to four months",
"     </li>",
"     <li>",
"      HbSC and HbS-&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia: Every four to five months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Penicillin prophylaxis &mdash; For children treated with penicillin prophylaxis, the dose in this age group is 125 mg twice daily. Penicillin prophylaxis is indicated for those with HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia and is often used for children with other types of SCD.",
"     </li>",
"     <li>",
"      Immunizations &mdash; Administer the pneumococcal conjugate vaccine series (eg, PCV13, four doses), haemophilus influenza type B series (Hib), and influenza vaccine. These immunizations are also part of the routine childhood immunization schedule but are particularly important for children with SCD because of the risk of complications if an asplenic individual contracts these infections. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link\">",
"       \"Standard immunizations for children and adolescents\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As of January 2013, a combination conjugate vaccine against Hib and meningococcus (HibMenCY) was recommended for children with SCD, replacing the standard Hib vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/26\">",
"       26",
"      </a>",
"      ]. A four-dose series of HibMenCY is recommended, at 2, 4, 6, and 12 to 15 months of age (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"mobipreview.htm?9/48/9999\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H182642754#H182642754\">",
"       \"Meningococcal vaccines\", section on 'In infants and toddlers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Caregiver education &mdash; Highlight issues of identifying and managing painful crises, fever plan, spleen palpation, penicillin prophylaxis (in children with HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia), growth, development, and results of blood counts. Review information on stroke, acute chest syndrome, inheritance pattern, and genetic risk to subsequent siblings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112754727\">",
"    <span class=\"h3\">",
"     Two to five years",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intervals for visits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia: Every three to four months",
"     </li>",
"     <li>",
"      HbSC and HbS-&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia: Every four to six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunizations &mdash; Administer",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23), with the first dose to be given at or after 24 months of age, at least eight weeks after the last dose of pneumococcal conjugate vaccine (PCV13). This vaccine is recommended for children with SCD because they are likely to have or to develop functional asplenia, and thus are at high risk for invasive pneumococcal disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"      </a>",
"      ). In addition, administer an influenza vaccine annually.",
"      <br/>",
"      <br/>",
"      Early meningococcal vaccination also is recommended. For children who did not receive meningococcal immunization during infancy, a two-dose series of quadrivalent meningococcal conjugate vaccine (MCV4, Menactra or Menveo) may be given two months apart, starting between 2 and 10 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/27\">",
"       27",
"      </a>",
"      ]. A single booster dose of MCV4 is advised every five years thereafter. The efficacy of the meningococcal vaccines in asplenic children has not been clearly established, but they are recommended for this group because they are at increased risk for meningococcal infections. Other details regarding meningococcal vaccination are outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"mobipreview.htm?9/48/9999\">",
"       table 2",
"      </a>",
"      ) and are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H19#H19\">",
"       \"Meningococcal vaccines\", section on 'United States'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Penicillin prophylaxis &mdash; For children with HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia, the dose should be increased to 250 mg twice a day at three years of age. Penicillin may be discontinued at five years of age, following the second dose of PPSV23 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transcranial Doppler screening &mdash; Transcranial Doppler (TCD) screening effectively identifies children at highest risk of clinical stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/16\">",
"       16",
"      </a>",
"      ]. A structured screening program using TCD, followed by chronic transfusion therapy for children with abnormal results, can dramatically reduce the incidence of stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/29\">",
"       29",
"      </a>",
"      ]. For patients with HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia, TCD screening should be offered starting at two years of age and should be repeated at least annually. (See",
"      <a class=\"local\" href=\"#H20573429\">",
"       'Stroke'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H8#H8\">",
"       \"Cerebrovascular complications of sickle cell disease\", section on 'Prevention of a first stroke'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Snoring or obstructive sleep apnea &mdash; Upper airway obstruction during sleep due to adenotonsillar enlargement has been found in up to one-third of children with SCD. If significant obstructive sleep apnea (OSA) is present, this may cause intermittent hypoxemia, which can promote sickling. There are no specific guidelines regarding screening for OSA in children with SCD. However, we suggest specifically questioning the family about whether the child snores consistently, has respiratory pauses of 10 to 15 seconds or gasping during sleep, is hard to awaken, or falls asleep easily during the day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/30\">",
"       30",
"      </a>",
"      ]. If these warning signs are present, we suggest consultation with an ear-nose-throat (ENT) specialist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      assessment with a sleep study (polysomnogram). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link\">",
"       \"Evaluation of suspected obstructive sleep apnea in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enuresis &mdash; The majority of hematologically normal children will become continent day and night at some time between two and five years of age. Children with SCD are somewhat less likely to be continent at night compared with healthy children. Education about behavioral modification should be offered to all families. Techniques include awakening the child to void to facilitate dry nights and offering praise when the child is dry rather than punishment for bedwetting.",
"     </li>",
"     <li>",
"      Caregiver education &mdash; Highlight issues of stroke, priapism (in males), home pain management, spleen palpation, importance of penicillin prophylaxis (in SS), and acute chest syndrome. Review fever plan, growth, development, and blood counts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112754767\">",
"    <span class=\"h3\">",
"     Five years to adolescence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intervals for visits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia: Every six months",
"     </li>",
"     <li>",
"      HbSC and HbS-&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia: Every 8 to 12 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunizations &mdash; Administer a second dose of PPSV23 three years after first dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/31\">",
"       31",
"      </a>",
"      ]. Penicillin prophylaxis can be discontinued following the second dose of PPVS23. Some authorities have recommended that the second dose of PPSV23 should be given five years after the first (around age eight years), but timing of prophylactic penicillin relative to this new vaccination interval has not been examined. Influenza vaccine should be given annually. Immunizations for patients with SCD and other causes of functional asplenia are discussed in detail in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link&amp;anchor=H4#H4\">",
"       \"Prevention of sepsis in the asplenic patient\", section on 'Immunizations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Complete the two-dose series of meningococcal vaccination (MCV4, Menactra or Menveo) if not already done, and supplement with a booster dose every five years (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"mobipreview.htm?9/48/9999\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H112754727\">",
"       'Two to five years'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transcranial Doppler (TCD) screening &mdash; Annual screening with TCD should be continued in patients with HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia at least through age 10 or as long as the patient&rsquo;s bone windows allow meaningful waveforms to be evaluated. A mechanism should be in place to track all patients in the risk group and to recall them for additional testing if elevated values are found. (See",
"      <a class=\"local\" href=\"#H20573429\">",
"       'Stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Education &mdash; Children with SCD face specific challenges in the educational setting. The following areas of concern should be reviewed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ensure that the child is sent to school every day possible and that the school is prepared to administer pain medications, if needed, to help the child stay in the classroom as much as possible.",
"     </li>",
"     <li>",
"      At every visit, the child&rsquo;s level of educational achievement should be reviewed. Given the high incidence of stroke and &ldquo;silent&rdquo; infarcts, particularly in children with HbSS and HbS-&beta;0 thalassemia, signs of poor educational performance should prompt investigation with a brain magnetic resonance imaging or angiography (MRI or MRA) and with neuropsychologic testing (if available).",
"     </li>",
"     <li>",
"      Parents should be advised of the federal legislative mandate in the United States regarding educational accommodation for children with special health care needs (CSHCN) such as SCD and should be assisted in obtaining services required to support their child&rsquo;s education. Mechanisms for accommodation include special education and other health impaired (OHI) 504 programs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32679?source=see_link&amp;anchor=H9#H9\">",
"       \"Support services for the care of chronically ill children\", section on 'Education'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional screening &mdash; The following screening is recommended to start somewhere after 10 years of age and to continue annually thereafter, because of the high incidence of dysfunction in these organ systems:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urinalysis for protein (microalbumin) and serum creatinine, to screen for proteinuria and sickle cell nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/32\">",
"       32",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dilated eye exam for proliferative retinopathy that may lead to retinal detachment, especially in patients with HbSC disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/5\">",
"       5",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H39#H39\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Retinopathy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caregiver education &mdash; In this age group, there is a gradual shift of focus from education of the patient&rsquo;s caregivers to education of the patient, as appropriate to his or her age and developmental ability. Highlight issues of pain, acute chest syndrome (and asthma control), snoring, enuresis, priapism (in males), growth, and development, focusing on early pubertal changes and growth. Review fever plan, stroke, blood counts, and spleen palpation. In patients with HbSC, splenic sequestration is most common among patients five years of age and up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10833324\">",
"    <span class=\"h3\">",
"     Older adolescents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intervals for visits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HbSS and HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia: Every six months",
"     </li>",
"     <li>",
"      HbSC and HbS-&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia: Every 8 to 12 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunizations &mdash; Administer an influenza vaccine annually. Verify that the entire pneumococcal vaccine (PCV 13 and PPSV23) and meningococcal vaccine series have been administered.",
"     </li>",
"     <li>",
"      Growth and pubertal development &mdash; Puberty may be delayed in some patients with SCD. Evaluation by an endocrinologist may be helpful for children with particularly poor growth (eg, growth velocity or values below the third percentile) or for children who have not started pubertal development by 13 to 14 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22424?source=see_link\">",
"       \"Diagnosis and treatment of delayed puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transition planning &mdash; The last several years of care in a pediatric setting should include a structured plan of patient education about the special health care needs of individuals with SCD during adulthood. The education and medical visits should focus on the patient rather than the family, as permitted by the patient&rsquo;s age and cognitive abilities. The content of this program should include the site of adult sickle cell care, including plans for care if pursuing college or other higher education, as well as the source of funding for ongoing health care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reproductive issues &mdash; Reproductive issues should be discussed with female and male patients. Key issues include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Review the inheritance pattern and genetic risk of SCD, with a focus on implications for the patient&rsquo;s offspring",
"     </li>",
"     <li>",
"      The availability of testing to determine risk of having a child with SCD, which depends upon the hemoglobinopathy status of the partner",
"     </li>",
"     <li>",
"      Medical facts about birth control (especially in females) including preference for progesterone-containing medications (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=see_link&amp;anchor=H12#H12\">",
"       \"Pregnancy in women with sickle cell disease\", section on 'Contraception'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased risk of maternal and fetal complications during pregnancy for women with SCD. These risks can be moderated with planning of pregnancy and with special prenatal care. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=see_link\">",
"       \"Pregnancy in women with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional screening &mdash; Continue with annual urine analysis and creatinine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/1/38937/abstract/32\">",
"       32",
"      </a>",
"      ], as well as dilated eye exam. Patients who develop exercise intolerance or chest pain should be evaluated with a cardiac echocardiogram to assess for pulmonary hypertension.",
"     </li>",
"     <li>",
"      Patient education &mdash; The provider should repeatedly review medical issues that require monitoring and should follow up to ensure that the patient clearly understands risks and goals. Highlight issues of pain, acute chest syndrome (and asthma control), priapism (in males), and educational plan. Review fever plan, spleen palpation (for patients with hemoglobin SC disease), blood counts, and patient&rsquo;s understanding of treatment options, including",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/53/25431?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      , chronic transfusion therapy, and stem cell transplant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8864714\">",
"    <span class=\"h2\">",
"     Other components of a comprehensive care program",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8864722\">",
"    <span class=\"h3\">",
"     Care plans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structured care plans are valuable tools. For a multidisciplinary team, a care plan ensures consistency and coordination of goals among providers and ensures that elements of care are not overlooked. Areas in which this approach may be particularly beneficial include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic transfusion care plan &mdash; This designates a location dedicated to scheduled outpatient transfusion and a plan for routine monthly laboratory testing, identifying specific providers to review results and to make clinical decisions on an ongoing basis. In addition to hematocrit, laboratory monitoring should include tests to determine the level of transfusional iron overload (ferritin and a periodic quantitative assessment of liver iron), monitoring of iron chelation, and determination of adherence to the chelation therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perioperative care plan &mdash; This includes preoperative preparation with hydration or transfusion, pre-anesthesia consultation, and postoperative care for common procedures. Patients with SCD have a high frequency of perioperative complications, but prophylactic preoperative transfusion does not appear to improve outcomes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H24#H24\">",
"       \"Overview of the management of sickle cell disease\", section on 'Prophylactic preoperative transfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain management care plan &mdash; A pain management plan can be customized to each patient&rsquo;s need, or it can outline a general approach, with modifications for a specific patient that are designed during a routine visit.",
"     </li>",
"     <li>",
"      Sports and physical education plans &mdash; This plan outlines special considerations about athletic participation for children with SCD, including standard recommendations and teaching for parents, patients, and teachers. In general, children with SCD may participate in sports with instructions to stop if tired in order to avoid overexertion, overheating, and dehydration that may predispose to sickle cell painful crises.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other components of a care plan address special educational needs (see",
"    <a class=\"local\" href=\"#H112754767\">",
"     'Five years to adolescence'",
"    </a>",
"    above) and steps in transitioning to adult medical care (see",
"    <a class=\"local\" href=\"#H10833324\">",
"     'Older adolescents'",
"    </a>",
"    above), as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8864729\">",
"    <span class=\"h3\">",
"     Other specialists for consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the large number of organ systems that are commonly affected by SCD, it is desirable to locate a referral pool of other subspecialists knowledgeable about these issues and willing to see sickle cell patients in referral. These disciplines are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anesthesiology &mdash; For perioperative care and pain management",
"     </li>",
"     <li>",
"      Cardiology &mdash; For pulmonary hypertension",
"     </li>",
"     <li>",
"      Endocrine &mdash; For poor linear growth",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delayed puberty",
"     </li>",
"     <li>",
"      Nephrology &mdash; For hypertension, proteinuria, or renal insufficiency",
"     </li>",
"     <li>",
"      Neurology &mdash; For stroke, silent infarct, or headache",
"     </li>",
"     <li>",
"      Orthopedics &mdash; For avascular necrosis of the femoral and humeral heads",
"     </li>",
"     <li>",
"      Otorhinolaryngology (ENT) &mdash; For evaluation of suspected obstructive sleep apnea and for possible tonsillectomy and adenoidectomy",
"     </li>",
"     <li>",
"      Pulmonary &mdash; For asthma or pulmonary hypertension",
"     </li>",
"     <li>",
"      Surgery &mdash; For cholelithiasis or splenectomy",
"     </li>",
"     <li>",
"      Urology &mdash; For prolonged priapism or enuresis",
"     </li>",
"     <li>",
"      Other disciplines that may be valuable for selected patients include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Social work &mdash; To assist families in coping with the emotional burden of SCD, in identifying resources for medical care, in meeting requirements of care, in addressing the child&rsquo;s educational needs, in developing skills of parenting, and in identifying options for adult care",
"     </li>",
"     <li>",
"      Psychologist &mdash; To offer individual counseling for children with mental health issues including depression, to assess for school avoidance behavior, to coordinate or administer neuropsychologic testing, to advise on need for educational accommodations, and to facilitate for the transition to adult care",
"     </li>",
"     <li>",
"      Educational diagnostician or school services &mdash; To inform parents about available educational accommodations and to help the parent communicate with the school about the child&rsquo;s needs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22723?source=see_link\">",
"       \"Patient information: When your child has sickle cell disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2030776\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All infants and children with sickle cell disease (SCD) should be managed by or in consultation with a clinician with special expertise in SCD. Depending upon local resources, the experienced SCD clinician may be a pediatric hematologist (often within a specialized SCD program) or may be a knowledgeable general pediatrician or family physician.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most infants with SCD should be seen by an experienced SCD clinician by eight weeks of age. The SCD clinician or team will confirm the SCD diagnosis and type, will provide anticipatory guidance about common early SCD-specific childhood issues, will teach the family to evaluate for complications that require urgent treatment, will develop strategies to provide requisite urgent care when complications do arise, and will determine the necessity for prophylactic penicillin. (See",
"      <a class=\"local\" href=\"#H112753070\">",
"       'First visit with a sickle cell disease clinician'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the first visit, priorities for family education include basic genetic counseling about inheritance patterns of SCD, teaching of the technique of splenic palpation to assess for splenomegaly (splenic sequestration), a plan for urgent evaluation of the infant or child for any fever (typically using a threshold of &ge;101.5&deg;F [38.5&deg;C]), and a plan for when and how to contact the SCD clinician should problems arise. This information should also be reinforced at subsequent visits. (See",
"      <a class=\"local\" href=\"#H20572848\">",
"       'Education and anticipatory guidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During subsequent visits, additional education should be provided about painful crises, acute chest syndrome, stroke, and priapism (in males). Families should understand these risks and should learn how to recognize and respond to symptoms. This information should be reviewed and reinforced at multiple visits. (See",
"      <a class=\"local\" href=\"#H112753092\">",
"       'Additional education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All families should learn about available treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/53/25431?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      , chronic transfusion, and stem cell transplantation. The indications, risks, and benefits of each of these treatments should be discussed and reviewed in detail when appropriate. (See",
"      <a class=\"local\" href=\"#H20573460\">",
"       'Hydroxyurea, chronic transfusion, and stem cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During follow-up visits, routine monitoring includes a complete blood count (CBC), reticulocyte count, measurements of growth, and vital signs (including blood pressure), as well as a focused history and physical examination. Oxygen saturation should be measured at least annually, using a transcutaneous sensor (TcO2). The frequency of these visits may vary depending upon SCD type, family needs, other medical conditions, and available medical resources. (See",
"      <a class=\"local\" href=\"#H112753106\">",
"       'Routine monitoring at all visits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional tasks during the follow-up visits depend upon the patient&rsquo;s age and include review",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      administration of immunizations and penicillin prophylaxis, as well as education of the family and patient about SCD-related health issues, tailored to the patient&rsquo;s age and medical condition. (See",
"      <a class=\"local\" href=\"#H8864157\">",
"       'Additional age-specific tasks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hemoglobin SS (HbSS) or hemoglobin S-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia (HbS-&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia), transcranial Doppler (TCD) screening should be offered starting at the age of two years and should be repeated at least annually at least through age 10. This procedure identifies children at an increased risk for stroke. In addition, children with poor educational performance or other possible signs of neurologic dysfunction should have further evaluation, which may include brain magnetic resonance imaging or angiography (MRI or MRA), as well as neuropsychologic testing. (See",
"      <a class=\"local\" href=\"#H20573429\">",
"       'Stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adolescent patients, routine visits should also include discussion of reproductive issues and planning for transition to adult care. Adolescent patients should undergo routine screening for renal and ophthalmologic complications of SCD. (See",
"      <a class=\"local\" href=\"#H10833324\">",
"       'Older adolescents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/1\">",
"      Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115:3447.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health, National Heart, Lung, and Blood Institute. The Management of Sickle Cell Disease. NIH Publication No. 02-2117, US Department of Health and Human Services, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/3\">",
"      Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics 2002; 109:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/4\">",
"      American Academy of Pediatrics Council on Children with Disabilities. Care coordination in the medical home: integrating health and related systems of care for children with special health care needs. Pediatrics 2005; 116:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/5\">",
"      Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010; 85:6.",
"     </a>",
"    </li>",
"    <li>",
"     Lane P, Buchanan G, Hutter J, et al. Sickle cell disease in children and adolescents:  Diagnosis, guidelines for comprehensive care, and care paths and protocols for management of acute and chronic complications 2001 file://www.dshs.state.tx.us/newborn/sickle.shtm (Accessed on March 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/7\">",
"      Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-care indicators for children with sickle cell disease. Pediatrics 2011; 128:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/8\">",
"      Crabtree EA, Mariscalco MM, Hesselgrave J, et al. Improving care for children with sickle cell disease/acute chest syndrome. Pediatrics 2011; 127:e480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/9\">",
"      Morrissey LK, Shea JO, Kalish LA, et al. Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer 2009; 52:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/10\">",
"      Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/11\">",
"      Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev 2012; 9:CD003427.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/13\">",
"      Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006; 108:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/14\">",
"      Morris CR. Asthma management: reinventing the wheel in sickle cell disease. Am J Hematol 2009; 84:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/15\">",
"      DeVeber G, Kirkham F. Guidelines for the treatment and prevention of stroke in children. Lancet Neurol 2008; 7:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/16\">",
"      Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/17\">",
"      Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999; 21:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/18\">",
"      Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin North Am 2005; 19:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/19\">",
"      Broderick GA. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. J Sex Med 2012; 9:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/20\">",
"      Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005; 106:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/21\">",
"      Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/22\">",
"      Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/23\">",
"      Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 2007; 21:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/24\">",
"      Zemel BS, Kawchak DA, Ohene-Frempong K, et al. Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res 2007; 61:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/25\">",
"      Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med 1997; 102:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Infectious Disease American Academy of Pediatrics. Immunization in special clinical circumstances. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering, LK (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/28\">",
"      Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995; 127:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/29\">",
"      Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood 2004; 104:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/30\">",
"      Wise MS, Nichols CD, Grigg-Damberger MM, et al. Executive summary of respiratory indications for polysomnography in children: an evidence-based review. Sleep 2011; 34:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/31\">",
"      Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/32\">",
"      Guasch A, Navarrete J, Nass K, Zayas CF. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol 2006; 17:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/1/38937/abstract/33\">",
"      DeBaun MR, Telfair J. Transition and sickle cell disease. Pediatrics 2012; 130:926.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14519 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38937=[""].join("\n");
var outline_f38_1_38937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2030776\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112753056\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112753063\">",
"      NEWBORN SCREENING FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112753070\">",
"      First visit with a sickle cell disease clinician",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112753078\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112753085\">",
"      - Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20572891\">",
"      - Medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20572848\">",
"      - Education and anticipatory guidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8865000\">",
"      Inheritance pattern and genetic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8865008\">",
"      Splenic palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8865016\">",
"      Fever plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8865024\">",
"      How to contact the sickle cell specialist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112753092\">",
"      ADDITIONAL EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20573400\">",
"      Painful crises or events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20573412\">",
"      Acute chest syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20573429\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20573439\">",
"      Priapism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20573460\">",
"      Hydroxyurea, chronic transfusion, and stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112753099\">",
"      FOLLOW-UP VISITS WITH A SICKLE CELL DISEASE EXPERT CLINICIAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112753106\">",
"      Routine monitoring at all visits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8864157\">",
"      Additional age-specific tasks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112754720\">",
"      - Zero to two years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112754727\">",
"      - Two to five years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112754767\">",
"      - Five years to adolescence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10833324\">",
"      - Older adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8864714\">",
"      Other components of a comprehensive care program",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8864722\">",
"      - Care plans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8864729\">",
"      - Other specialists for consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2030776\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14519\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14519|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/36/32331\" title=\"table 1\">",
"      Symptoms requiring immediate care for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/48/9999\" title=\"table 2\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=related_link\">",
"      Acute pain management in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=related_link\">",
"      Diagnosis and management of priapism in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=related_link\">",
"      Evaluation and management of pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=related_link\">",
"      Management of fever in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22723?source=related_link\">",
"      Patient information: When your child has sickle cell disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=related_link\">",
"      Pregnancy in women with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13960?source=related_link\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32679?source=related_link\">",
"      Support services for the care of chronically ill children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_1_38938="Poison ivy 1";
var content_f38_1_38938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81397%7EDERM%2F54814%7EDERM%2F81173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81397%7EDERM%2F54814%7EDERM%2F81173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison ivy leaves and flowers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Green or green-reddish leaves grow in groups of three and have smooth, fine-toothed, or lobed margins, and small, yellow-green flowers form cream-colored fruit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison ivy fruit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cream-colored fruit of poison ivy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison oak",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38938=[""].join("\n");
var outline_f38_1_38938=null;
var title_f38_1_38939="Foods better tolerated PI";
var content_f38_1_38939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Foods and beverages that are better tolerated by irritable bowel syndrome patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Water, Ginger Ale, Sprite, and Gatorade.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soy milk or rice milk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soy or rice based products.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plain pasta, plain noodles, white rice. No sauces or gravies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potato: boiled or baked. No French Fries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breads: French, Italian, whole white, English muffins, and white rolls.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plain fish, plain chicken, plain turkey, or plain ham.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eggs: soft-boiled, poached.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cereals: Plain Cornflakes, Rice Krispies, Corn or Rice Chex, Cheerios; dry or with soymilk or rice milk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salads: lettuce, hard-boiled egg slices, oil and vinegar dressing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cooked peas, carrots (avoid raw vegetables).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Margarine, jams, jellies, peanut butter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In small amounts: applesauce, cantaloupe, watermelon, honeydew melon.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In small amounts: fruit cocktail, peaches, pears (canned, non-dietetic).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Substitutes and alternatives are available for the foods and beverages that induce gastrointestinal symptoms. Listed above are examples of some of the foods and beverages that IBS patents have found to be well tolerated. It is important to use daily vitamins (multivitamin, calcium with vitamin D, folic acid, vitamin B complex, and vitamin C) when on a restricted diet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: MacDermott RP. Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis 2007; 13:91.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38939=[""].join("\n");
var outline_f38_1_38939=null;
var title_f38_1_38940="Features neonatal seizures";
var content_f38_1_38940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical characteristics, classification, and presumed pathophysiology of neonatal seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Focal clonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Repetitive, rhythmic contracts of muscle groups of the limbs, face or trunk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May be unifocal or multifocal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May occur synchronously or asynchronously in muscle groups on one side of the body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May occur simultaneously, but asynchronously on both sides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cannot be suppressed by restraint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathophysiology: epileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Focal tonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sustained posturing of single limbs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Sustained asymmetrical posturing of the trunk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sustained eye deviation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Cannot be provoked by stimulation or suppressed by restraint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathophysiology: epileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Generalized tonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Sustained symmetrical posturing of limbs, trunk and neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be flexor, extensor or mixed extensor/flexor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be provoked or intensified by stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be suppressed by restraint or repositioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presumed pathophysiology:nonepileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Myoclonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Random, single, rapid contractions of muscle groups of the limbs, face or trunk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Typically not repetitive or may recur at a slow rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be generalized, focal or fragmentary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May be provoked by stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presumed pathophysiology:may be epileptic or nonepileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Spasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be flexor, extensor, or mixed extensor/flexor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May occur in clusters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Cannot be provoked by stimulation or suppressed by restraint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathophysiology: Epileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Motor Automatisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Described in table \"Motor automatisms\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Mizrahi, EM, Kellaway, P. Diagnosis and Management of Neonatal Seizures. Lippincott-Raven, Philadelphia 1998. p.181. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38940=[""].join("\n");
var outline_f38_1_38940=null;
var title_f38_1_38941="Incidence rates of syncope";
var content_f38_1_38941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incidence rates of syncope according to age and sex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incidence rates of syncope per 1000 person-years of follow-up increased with age among both men and women. The increase in the incidence rate was steeper starting at the age of 70 years. Syncope rates were similar among men and women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347:878.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38941=[""].join("\n");
var outline_f38_1_38941=null;
var title_f38_1_38942="RMSF rash PI";
var content_f38_1_38942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rash caused by Rocky Mountain spotted fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 178px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is what the rash caused by Rocky Mountain spotted fever looks like. It usually does not show up until days after the fever starts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fatal Cases of Rocky Mountain Spotted Fever in Family Clusters - Three States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:407.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38942=[""].join("\n");
var outline_f38_1_38942=null;
var title_f38_1_38943="AVM posttreatment angiography";
var content_f38_1_38943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 327px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFHAUsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKdGjSSKkas7sQqqoyST0AFeieFfgz4z8Q7HXTf7NtWG4XGoN5KkcHhcFj17LQB5zRX014d/ZpslaKTxD4illGQWhsoAoxxkb2J9/4fSvQ9H+CngLTZ8DQxdsAyMbu4eXPOc4yFH1xQB8RVPFa3ErokUErtIQECoSWJ6Y9a/QrT/D/AIc0ZHjsdA0e2t5jlhFZxjdgYBIx9a3IdRVgqRfKq4CKDj8vTFAH50v4a11Bl9F1NR72kg/pULaJqq/e0y+H1t3/AMK/R46jPniXJ7jk4/xqwl9M3XzFAHJbj+tAH5lzRSQyNHMjxyL1Vxgj8KZX6azxWtwzPPaW0rnqzxKxP4kVyl/8M/AepRlLrwno4LNvLRW4hYn/AHkwf1oA/PWivs/xB+zZ4J1CP/iVS6lpEqhjuSXz0YnplX5wPQEda8x8U/sv+JrFHm8O6jY6vHn5YnP2eYj6N8v1+YUAfP1Fbninwlr/AIUult/EWk3enyN90zR4V+M/Kw4P4GsOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoor1r4dfBfVvEax3muGTStNYBkBUGaYf7Kn7o92/I0AeY6Vpt7q19HZ6ZazXV1IcLFEhZj/wDW969s8Ffs/wB3c4uPF199jiI4tbQh5c/7TEbV/DNe8eGPDOj+GLEWuh2ENpH/ABsoy8h9WY8k/WtyNW4IAxQBz/hfwZ4e8Moo0LR7W2lHH2hk3yn1zI2W7diK6WPJA3k+9OGcc05OuSMj6UAPEJVsr0z3NTDGRuyfpxT1cBkJAwpB4GDTklJbndyMcdaAJredYkCSK/UjPpVgrFkEhMnkHjmq9vc9FkP/AAKrKHKjAAHt0/CgB6NGScj5h7f59KmBQnjH5VDg7c/5FPVTtztyaAJCY8ZwMfSgpERlc49TQm4nnAGOlKMgDgD2oAjMMbMCC34Hih1fJ8iVSB2YVLk9CtNlJC8fjQBSVkv/ADLK/t4JlXkxyIHU++CCP/115X43/Z68HeImludMSbQr58tm0wYS2OMxHgDPZSK9MtVkXVzuLZKkkHBOOK1yOOAOaAPgf4i/Bzxb4GDXF7ZC+0wbiL2yzJGoHOXGMpxzyMe5rzmv1ABK9DweteL/ABT+Afh/xe819oZj0PWmy7GNM287Hn50/hJP8S/iDQB8T0V0PjTwdr3gvUxY+JNOls5mBMbHDRyqD1Rxww+nTPOK56gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAq3pen3eq6hBY6dbyXN3OwSOKMZLH/PftVnw3oWo+I9Wi07SLcz3UmTjOAqjqzE8AD1r60+G3w+03wXpwSILPqcyBbm7Ocuc5wo/hUfrgE0Ac/wDCz4O2Hh1YtR15Y9Q1cgERsoaG2PHQH7zD+909B3r0q8vriLVY7byozbuhYys3LOD93FXYz5XrjpVW/iDPEWUmQEEfyoA0oG3IrSDGR0qeMAHkkEdqq2/MYGeehq3HyOh470APHA4z+NP4C9fwptKOnAzQBNgqcICSPU9KUHj5vl+ppkROTgE8c1L9R9KAHrtJ5yB3q6h2KAjqwzgDcB/T3qiDlgAoOBnFW1gidVflQR0z3oAsqzDjgNj6gU8Ow75+tNx82RwTgZocHbjjPuMigCVX65Lc8dacHI5DBu3oaiijVD8qqMckgYqYAMORnjgkUALvGBnI+tKSMHBHHpTQg27eaZPbhwACACOcGgCjbMZ9VmKH93Cu3PuTWpUdvClunlogVc54/nUwYDAA4Bz70AIcE8Ck2jOccinjYQeMHtQRzgYK59aAMTxL4c0rxPo8+l69Yw3ljIMbHyGU9mVuqn3FfG3xk+CereBZZdR0rzdU8N54uFXMkAxn96AOB1G4cH2JxX3IwJ2jHOKingjkikhnjjkglUo8bqGV1IwQR0II7UAfmFRX0X8f/gb/AGMl34n8Gwj+ylBlu7AZLW/OS8Yx/qx3H8PuOnzpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFX9E0q81vVbbTtMhM13cNtRB+pJ7ADknsKpIjSOqIpZ2OAoGST6V9WfB7wAPCGjvPfKh1m8Qea3B8lf8AnmD+p9T9KANX4beCbLwZonkW5SbUJgGurnH32H8K+iDsPxrsMhEMjk7cbsjmm2yBY9nc9yKfGkryGJ0AiB4OfvD6UATafepd2azRFgrDK7lwfpg02Rt8pLDkEAUsASJdmAMc+lVnlJ1CFYjmMglyB0I6UAaqcOw7datRcg881m75FuolbGxgVz3zwRV+H72M0ATAYHenp97g4NNpePxoAkTcWPzA1LkZA9agQZIz8o/KpGIAIXgn9aALFqoDgkhSW4I/wqxCDE5QOpUnv69x9apQxoV/eEq3HIp6BfOU7SwXnn9aANFpFRC0nygepHNQfaJZMGGE7fVu9QWmL2V7hgNgOFHrWko5H9aAIvNlAUmEDHXaeakim3jIB56hh1oOSODinBQpUE7vUmgByyNgYwR78HFSAlvajCAZAHpTgMDkrn270AChwO7AdcU17fzIwC7RjvsOCKeBjpT8HZ0I7/UUARohiOwt5ijox61IhO7d+HTrTVU5OTj68U5eW4GPTvigCU4ZQcc+9MZCWOSTmlC4I5J4qQHI96AKzL8pDjKnggjIPtXyV+0r8Hv7Imm8WeFLRF0l+b6zgTAtW/56Ko/5ZnuB90+x4+uvL9B09aZcQo8TpIiyRuCro6hlYHqCO4oA/L2ivYf2ifhX/wAIFrceo6Osj+HtQdjF8pItpOpiJ9McrnkgH0JPj1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFbngzw/ceJ/EVppltlRId0smP9XGOWb8B+uKAPS/gD4LW7ux4k1SL/R4W22QccPIDy/uF6D3+lfQ1vL5gIyu9euD+tZ2k2Ntpml2tlZIEtbeNY4164UDv6n1NXliVkLrhGPccfnQBOH2kEDPOOKuK4UE8fX0rPteYjvXDZxg1g60t5qd39lguTDZRuqzKq8yc8gnsPpQB0aKLqYykbkX5V7/AFNWUCrcDAGNuBxTbdFihREwFAx60qZ+1YzxtGCB3zQBPMNrQ8cbsVZGVIODULoHiZQxJ7HOcGmoZZUGW8sjrnnmgC+Dxu7H2p6HLcZ/CoojnJxz61JQBJEDuJx0HX3p8gUhSwJANR2y8HdjPXg1OM4Kk8HtQAohlwCm4g8jjNEwlPBhJYj+DnA6dKWI/wC0Qc46+9WkOxjlyd3TByTnp7cYoAxLHUv7OZoLuN0Xd8pPSugt7qGcAwyKx9AeabJbpcI6XARweoA6HFYsGmW/2cyJK8L5Krt74oA6T8eop8eWGMn061y8tlq1rDvt7kMq8mM9a0/D2qG/gbzBiVDtdaANoKB0FLTVHHBPBp340AFKOMGkPQ4BJ7Ad6MSMcIpPqBQAowxOTil+7xwR/Oja4ODww4wO1KSD1GFHpQA9SG6D2xSbgDyN2eTgcCl4OQp2jrTVUHnqKAJVbPOOtNZm4K4we1NDDgDtwD6099xxtIH1oAxPFPh6w8UeHr7RdXiEtleRlH6EoezjPRlOCD6ivz2+IPhK/wDBHiy/0LU1PmW7/u5duFmjP3ZF9iPyOR1FfpAVAwck+uK8W/ak+H48VeC/7csI86toqNL05mturp9V+8PowHWgD4looooAKKKKACiiigAooooAKKKKACvo39n7wyumaBLrV1GRd6gMR5H3YAf/AGYjP0ArwfwtpEmveIbDTIc5uJQrEdVXqzfgoJ/CvsqwgitrWOCBAkMSiNFH8KgYA/IUAVCzKuY3Yqcll64Ge1akEkT4ETDjk81TuLc+assLMGU5KD+ICsy81PSdEu0mvWjtzfyiONyp+d8dCe3TvQBu3Mxtg820sm0nA7mobKGRNJjadQJZWUyexJyabLcJqLxwWxEkZIaWRTwPb8a1tv7llIBVhg0ASQtlQp+8tFqQ0jk55b/9VZbzrZWLSyyhFhyCx6ECsbS7u717T2NuDCrEkO2RnnqKAO8XoOMexqhdee5Mdu/lsXzuxnpzWfo13e20RtdSRzMh+WXjDL7+9a0LpMGKSLvByCKAL9q5khVm4Y9RTpW42jqayTcG2aRrmWKC2LfeZtoz9asR3kAC+Qwmz02cigDUj3KMJ9KlkIWNjzWfHduh+eCUcdcZp093C8bKGYvjAGMGgC9BlUHPzYyce9WoJVUszruJ6e1Z0MlwANyJkjoo5A/Gp4Q8rAOpUdgTyT70AWbq7IjcRDIc4D9M8VYsoljiTY7NhdvPT3xXM+INTbTr2wiMDlZWZWkAyEIHfn+XpVi5ure2sDdT3Mkqj7gU/ePtQB0s0qJCXkKLEoyWJ7Vyvg6f7Zf6hcwDNqZCqOvQ471zp0DWvFUm68v5rHTm+b7OjcsP613Gl+H7Sws4baEyGOIYALdfrQBt5IXdvA9sd6dG2RweepzVFNNiA/dhomzwyyGplNxb4Vx50Y4DL978R3oAuDaM9cn2p284AycDsKqid3+5BJ6fP8tMfz2k2mYRgDJ2r+mTQBb3Atj88UvUnaOlVrOOdd6MxZM/IzdSKs4KjBBAoAk2Dp94jjJpeSOOAPTp/wDXpqnkjPB/zmm55G1hgdPmFAD2bJ6N6HPFLyWwuMDoaa7Ejrx2pFYKvuaAHhsBcAnPTmmtwTkZRu3rTfMVT8xxjpimtKW+UZwOpzQB8F/tA+CF8D/ES7t7KIx6RfD7XZegVvvJ/wABbcPpj1rzSvuD9p/wd/wkvw0nvbOHzNR0Z/tilR8zQ4xKPoBhv+AV8P0AFFFFABRRRQAUUUUAFFFFAHs37O+jB7nU9blUkwgWsPpluXP1ACj/AIFXupn8lQxyWf5UQdSa4z4U6CdK8EaYiHZJcILqXcuG3OM/oNo/CuqliKlZFkJkiJP1B6//AK6ALVvdEsy3CiNuowcgiuf12zTWNWgjjnlj+zguXhI4Y8Y54zirWspNdtbw2xRWbLeY3IQe3vWHNrGm+G7OSOGYXN2h3NEGLFifX3oA7rSGH2RYyArp8pA7n1qDXfEunaDayPeygSKu4Rjlj+FeQRX3jO+1Y3IjlsrOc4SaQlYo/Tjr/wDqrvdK8FRBDf6veNql8fmVm+4v0H+NAFa0h1HxRCLzU4ng04ZeO1QYaT3Y/wBK6nT7iMgJBLDBboAgAYZBA6e1asUSfZw0BCgjPtmuB+H9zPdeJNbs9YtbdJIZMphQdw55zQB6Ja2lvIQxbzuOrHOanjs4Cz/IBz2GKpSlLJ1kiHl7jtIHRs/1rVtlKxKp5Y9frQBi614e07VLKSx1FDLaynIyxwG7VQ0CG+0C7OmoYZ7fbuh3fK+O4HrXWyxiWJ4nUMPX0+lZ+2NpoEmVXuYW+Rsc4PGR+FAGjZ3iXKHIMbr95WHIqSQASbwuW9AKqagDFLDPEMFWCv2BU1bt5HR2Ese5s8FRwaAJ8+YwBAX1NWOeCrH1zjmqBa4Z2YbYw2MbuoFKou4ssJvOHQrjGaAJr6xt7638m7jWVM5AI5B9R71y2lwNNrUlhL81vZsSMnJPAIJFdZBOssJcDBH3h6GuZ8L3aXPiHVVCFHQjOTnOenWgDvrfCxqEwVHTAwP1qdWA6cE8ZrnfFVxqNh4fnutG2farUCZomG9ZFH3lPfpzx6VzPhr4qaXf7ItXQ6fcHjf96In69R+Ix71lKtCEuWTsd9DLMRiKLr0Y8yTs7br5f5Hpit1GAcelPBzVGCeO4hWa3kjkjYZV423KfcEdanhlxuWQorr97ntWpwtNOzLFA9aojVrEyiNbhGcnA28j8+lXVYEAjmgRDdXUdqqlyxZztRFGSx9KYv2m5z52LdD2RsuR7nt+FR38fl3FtdkE+SSCPY8Zqxc3kVuoeXlm+6vc0APjtYMZZWfnADsWz+dRTWto+c28ZJ7BRwKpXE8KyFruaQBuFjOUUj8OakR0iRTFaSIcjhF60APj0u3jw0QaEqeBExHWrBtncHfcy4I7YX+QqSBy8SuylT/dYU92WNCXcBQe54oAEiVAQCBjvUcahS/TJOelOW5SYExK0hB5PO0VVd5I72JSyFXXBUDJHpzQBZmiiuYJraVN8M0bRyD1UjBH86/OP4g+HJPCPjXWNClJb7FcNGjkcunVG/FSD+NfpBEmApPAzgV8lfto6Atr4t0XXYUAW/tTbykDrJERgn32uo/4DQB850UUUAFFFFABRRRQAVd0WyOpaxY2K8G5nSHOcfeYD+tUq634VW8U/jvTPPkEccTNKSR3CnH05xzQB9UwsIkRGH7vopCgY9BS37M3MJ+cDkAZyKy7lrxgIYSh3D5pG/gH071U8QeIIfDfh+e+uW3svyoDwXbsKAOV8fanJqGn6foOnGUarcupYr8piXPU46V1PhrwpZeH7S3t41+0XcjBpZ5PmLY5JHpWb8OtBl3S+IdXBOoX58whv+WanoK7e2iSS9llx9wbFx+ZoA0FRWBU4KgY6VS0gCL7YoysazHAJ4H09KZqWrQ2cLgjlePWsTQNO1G7mvrnULiSKG6m8yODoUXaB+uM0Aa1/qq2Uix2oaTzTt2r2Y9MVRi0yNpJJ7YONVPLOrYC+gat5dMiS1IhGGHO7vkVFoKQy2wmx87u2/P94Eg5oApWEupX14lrq0EFvFEN29JNxkPbHoK6e3l8shJGyf4T6/8A16hmhjlQEqOORxWc9uLm4RYZWjSNgzEd/wDZoA6RSMAgkfSnBkLZKAt0BxzVKKD5dzO341KkUYHGW980AO1SbZb7MHLMFGe/NWYJv9tfTrzXP69q2naZJbyalcw20KsfmkOMn0FZtz4/8Ow31nZR30UlzctsiCLkE46Ejp+NAHdpN3PIp/mKRw3t9K+cvGPxo1LTvFQsNPtbWWxTZ5spjYsucZxg44H5112m+KjZ3MWqS341LTrwn/Vrh4eOBs+vf3oA9EvbqODUihk2iVMuPSuWh1yw0fxL9pZ5PKvMqzeWdoOcDmrvgqKbUUutX1SPyp55CFiY5McanCr7ep+tZ/jXxFpFlaHTXvLdLgyfKMFsD8KAPQE1m0kiXEm8A7jlSfwryOXwJd3XiK/Gm2ryachMsIPyeYDyEyemOhPt7103w28W6fr3m6es0b3dt/cPUDivQ7YRCQrK7AN0BYgGsqtGNW3N0PSy7Na+XObo/aVv+D+f3mN4R1KTUdJ8rSltbD7KfJlsWUhoGH8JHX157/XNaFxpF1qeItSmjW3DZZIAVMmOxPpXO+NrJrPVrbUPDhaLXAMSKp+WeP0fJ9uv/wBbF3woIfENg9y97erqEZ2XELfK0Mg6gr6eh/8A1U4SafJLf8yMTRjUi8TR1i91u4t9+6fR/J6nYm1tPsv2dYlSHGAoXGPpVaK6NkwguGyCcRyEfKR7n1qodP1MIscGrSAc58yIE+lRSeH5LidBqWo3N0Np+TO1fyFaHAamqXcJs3jjZZpZRtREOSSasQWEPmwzSRq1wkYTdnOMelZFp4V061ZpLQSwSnq8cnNTtNe2D4uCbq2/vquHT8utAGq9lC6FQm7cOS3LfmajQXlt9145kxwG4NPt7qGWISxTIYyPvZFNN3AYXkSaJo0+8QwOPbIoAW3uROJBsZXi4ZW7VUg8p/38gaedudqjcqew7A9Kw9PudQ1uS6CJFBGT5cjDPQE8D610sSi1jAlWNEQYGzoPwoAei3Mg3FUiX0B3N/gKdHGBLySTjqetSRukmGjO8HpzTjtJO3buH3hnpQBJGDt5J6141+1poY1T4ST3qgmXSruK5XC8lWPlt26fOD2+77V6+1z8xSON2IPJHQVz3xG0xtZ+H/iTT28kNc6fOqs7HarBCVJx6EA/hQB+cFFFFABRRRQAUUUUAFeifBXSpNS16/ZJUjWK0IO7+Isy4H6GvO69f/Z3s4ru+10S5+WGLBBwR8x/woA77SI70akdN1SRsAbkBJ/eAdOa5XxlbNf/ABA0DRyri38wy+WzZQ49j9P1ru/E1s+nRW19HM8n2aQEhupU8HmuW8fk6d4s8OeIUXfbq/luFGCM98+nNAHp8M7xIyzxhOMDbyPoDXKw+O7O2muYLq3u7Z/NIV5Ijt9ssOB+NdZbTC5jDbMqwBB7HNVNa0YTaZdRWiwxyzKV3FeCcd6AK+kqmouLtz5kY5Q54J9fwrqbcjt94d/avNxp3iLQrBDpcunR2yptEEu9kjOOueoGe1VfBfi3X5JDba7pDy3Ui74JrQZjmXJGTz8vagD1gvsHpnisPRJwt7qsQO1Vm3KOwyBn9arR6zObh4b+0+yskBmBMgKlR1ye2Kq+CtSi1PT3vk/1M5zG2MbwO/0zmgDsmlAjzuySOPeq2msUhIYgszGs3U74WWkT3DEEQKZCO5A5rL8N63dXd6tvfWgt38gTR4fduUnv6GgDuMkr7gda5P4hapPpWlRfZ7n7IjuRJN/cAHb3NL4q8THRraTyohJKsYb5s454Ax3J9K8u8Yw+J/EhitNQntliCi6a1AwEA6Bj60ATDwdqPi2BfEPiLUJbpoFDWdp90MqnO4gdCf1qaLTPD/iTWtKs9ES4hWKTz7weWU8ooMYLH616b4Sv4msY7Wa3+y3MSANE3ce3qKrePtWj0vQ5VhQLc3I8qJQuDk9W9aAPK9I0qbWPiJqsVibeW2kxGXZPuorDoPwrtJvhhc2VwbjRblI2b/lkwwv6da0vhP4dOjx3c1yGN2+Axbkj8fxr0qKTC87vr2oA8n0Ox16TUBZazqaW9rKxUiE8lh2z7jmvQLLwZoCRoJNPhuJF+bzJV3Gpb7RLK/1O2u5WZJbdtyqj4DHHcCtRkkt4DIh4UZweaAOOsPhRaWHxKt/FemXv2O2KFZrGJeHYjGc9h0OK9L1KaGz06WSU7Y0XP1PpWTbXoMHyQs28DaSvT3yaxr0yanq8djLMBaW6+dKqj7znoCfTvQBoaJaTS7r2+hcS3HIB/hXsOfzrqbVVjQlIkRnILFe5wBye/AH5VS07ZdRh3Xeo4TPStNdokVVHy46dhQAoVkwcAnuSay9d1T+yBHNKp8p2w8nJCL1JrYPp1zUF3ax3cRgmXdEwIK+ue1AFHTfEOn6gF8iUgMAVLqVDfTNaIVVDOzHknqf89q5e+gawtEtJY1ubEqVjGdsiewNcP8PtSvteudV0H7fc3djYTlZpWcNIUzxFu7CgDsJNSsItXubezsW1CTG9PLTKg9CCenWqmhR3mpyTSi3jgE0rMdmNqds8cZ4roW06G0eB1h8i0jPleWO6kdTj3rQtvs1pALTS4IwsYwEjGET6mgCaztY9OsoreIZ9OeWY96njhdCZJiGkbv2A9AKIFKZaRt7t3PQew9KlcoFABBNAEH7trh41+clenp9altLKG1iVI02LnOAeM061A2sVxk1MWUHAIz6UANdcLgZxnOKfH5bEqyAg/KQV4oPSnIypguwAHrQB+YOt2v2HWb+03bvIuJIt2MZ2sRnHbpVKun+J8UEHxJ8VxWiqlumq3SxqvQKJWxiuYoAKKKKACiiigAr2H9nObytS1ldjMXSIAjoOW6149XsH7O7j7ZrkSoWmaOJl44ADNnn8RQB694yV59DvIoE3uIyTzjHf+lcv4oha98A3EMdrcXBe23xoq8owGck+ldvMAunTRT/M7qclf4s1haJcCfwlNGxcTxRPG0b9VIBGCKAM34V3Ws3vhGwuZbmKUoDH5bx44UkcsOc4rtDrPkusOo2MsG7gSqdyfiR0/GuR+BtzFP4HSJGBlimkWRc8qd3cVa+IuoX9pPpFvaTR29peXPkXMzJvK5HyjnjBIxQB1c7KY2TYZUbggrwR+NZmnWtxazJcrHuwGQwI2Ai542jpVLwjqwuJLnTbuVDc2jbCQRyval1bVbi4vZNO0Bke4X/XXBwy24/q3tQBia7NNrXxCt9IeJoraOyMtyN4+cFxhTjpn0ruAn2dIktlVFjXAVQMAemK5/T9Djjj821nZNRDbnuH+YyE9cj0pmoQahK0aSatKsr/AC7baMKAO/WgBvxI1q103wrLc3YZ42ZUAQZJyelSeCra/wDsM1xO0LeeFKNnLIgHC+nFeW/EGTUpNRSxie81HTYSoO2PcRMeAjEdu+a9j0GzSGxhWENbsYxkA5UHHPBoA5bxzA8XiLQ0spy9yFe7nSdjskROeT2Oav8AgG21PWmn1XVoIreC5lEgQNuLgHgewrB+NcfkWem31vPI2qofKRFwMxH72QK76DXbDRPCFneSuRAsC7eMbuKAHeO7/TNM04Xl5P8AZbiLJgZeGLen0rhfAmtReIddk1fxZOtvNbj/AEaNwVjcf3lJ4OPak8OaVe/EPX31vV18nRonAgiP/LTB6fT3r0bxJY6Y+nRC6ZLRomCwuU4U9gBjke1AGh4UmW9hubyLPkTSsYyRjI6Z/StK5vpGlFnYbfPx87tyIx/jWBZXPiCe2WCOzgi3DH2hnGMeu36dq29Esfslu0CuZpGYtNN/eNAEMfh+J5WmaaVwQeS5yT6+1La22q2pnis5hdWoHypOcMvsD3/Gui2jyyNgx37VnO9wjOsAXaDlpR1Htj1oAz5dbmht2EmmTeYMg4IwD3qTQbYpBPOjbru4fc5DcY9Pyp9tcQysIbf51B6scBj/AFq/a6bNDl7SAEZLccAn/PagDV06MwQJDehwEyARnHJ9a20YY2gk8elY4vL6JAzWoY8ZCjJqs2ryhj5dnICeSGP60AdI+COvzAZFZuoarDZLiTe85+7EnU/4CqgGoX6fKVtlPdTyfpWhp2l29nh0XdL3djk0AY0dpeauS94hgtm6rnnHoM1f0rw7aaN5v9kqtoJ23yYQHe3qfethiqgs3YdhTHuUj2GZDGHO1QTnk/SgCrcaabyJoru4lljbjauEB/KjR/3Vm1s6hXt2KHAxx2P5VoqcsNuT3FZt5FdxXEs9mI5DIu2SOQ45HQgigC88jCIySOEjzxjsPeo45kKeYEkZfXYef61X06C6mijuNUKedgEQxEmOP8T1NaoJI4GCfSgCnaTpMrMImVAxUFuC3vjt+NSRwo9ysuxdy5APfmn3Fuk0WMkNjAZTg1BFFKqLuuZWUDgEAFvagCe4mZf3cA3THoOy+5p1laLCw3vJK/UtIxb/APVTLeFbdcRR4zySWyT9atQs+RlCBnHtQB+bnxRYN8TPFpHQ6vd/+jnrl66T4lEH4jeKiOn9q3eP+/zVzdABRRRQAUUUUAFeqfs9XTR+Kr+2DKBPaFsEcsVZePyJryuu6+C2ofYPiHp24kJcB7dsY/iU46+4FAH0mJUkMhlb5xwB/drkrxJ9Ov3m0vNxvP76NjkMcn8jXYNHG0++MKQvLU+IxtIiFVBJyeMZoA8ei8IW412a70zXr3w5cTnc0DoQuT1CsCBj61Nc/Dy/1XXks9Z8S3l9aFA8ZjfLDr8xByOv869c1PT7G7UQXUCyq+cp61BoOhaboomk06zigMuA5TrgdBk+lAHh8/wv1SDxgljDJeiykj3PqAb68fXpxUVv4a8aeALS91KzuLP7FHmSQGQESAcZKnv7da+gdVvLezsJrq5mSCCBS7yP0UeteKfGLVP7XtPDuladerNFfy7mZThScgLkdepJ5oAh8F+LZNdeSS9106fqO7iJlAiYdsc13X2HXrzBl1S0jhI2+bbRfOR3weg6V514u+Hum6Rpum31usohVxDdESZLHOCwz0z6V0MPgTWdPhR/DfiS6W1kAZY5ORjtjtQB6H4Y06207SY4LfJTli7H5jnnJ9/es3xD4q03Q4bgTzK07nEcCNlj/hXJw+EPE80LQ6h4quI4+gEankZ+vpWPcxeHPB14t1fztfXUTbgpcSSFhnBx0GfegDsNIsWu7S+8S+LT5O6Flhic8Rpjrg9/SuR8B6ZqPj+SH7c0sXh6wdkiRcjzOf1+vaqd9f6v42RbjUGeDTGb/RrNPvTN247+5P4V7P4E0ZvDvhm3tIYghVS0gz91j1oA6vTLKCzt4oLdRFCi7VQcBQPatB4VdQFVT9RmsS11zRzcNGdQthImQweUAj8zVmfXbZMJaxvclunl4AP0NAF97O3V90YMZxhgvA/GrCzQ20IVeQO49az4FuLn948YQY4y2cf41Ymi2xZwXcc72/pQA4zz3Kn5GWMdFzy1LLBPOqxqojj6bPXPrVmKeGKCN2YZAHfJz7VctZ2BLhWyw64+6KAGaVo8NttjRBwuQx4x7ithPMicCSSMxY4yMGqSvEX3OGOBjDN0HbFXIhbEZTaeO5/xoAiv77yAqxAuzDGV7VYEMT242qcsM7mHP1qHUYgLV5IYkMqDcu7gZ96rafq/mKGkjKJnAmUHy2Pcjvj60AWwrIiCVWfAwGUDK/h/+unwttY4mmVeuGXH86txSRzqcMj9uCDTnKRqoI9lUdT9KAERBxI771HOeMD3qCaz825W6QqrpkJuXdn/AA/Co/sjNKJXjjVAciNM5z657n26Vc86PGN4Bzgg9QfpQAyK4zII5o2jkJwOMq30NWGZcHnHuSP5VC8H2iPD565GOMH1qrLbToRJblHccbcYLfUmgC6ky4IEhIBwSOcflU4IZsk54xzxVWENHEAQ27uHPOfrU28OuSuG/iWgCdS23OBj0FMCqrgj+LoRSoccLgr6elKUTqRg9aAJBwfWpFcKCxwAOSegHuajA4z09q5/4ias+heAfEWpq8YltbCaSPzMlTJsO0Ee5IFAH5ya/cve69qV1LJ5sk9zJK0mc7izEk/jmqFFFABRRRQAUUUUAFXdFvm0zWLG+QAtbTpMAe+1gcfpVKigD7Ni1WzdAFkCZ55GOMdcVU1S2utSZWsTHbpjmZ1JdvoOwzWT8K9Ti1XwJpc5bdLFF9nlLDncny/y2n8a6vfGoLDgHngdaAKlhZ6laBmklguZPdNn65pxur0S7Tpztz2lWrwlicbpMK4HUmlCwYG73xuY80Ac34uR9U0w6bNZ3kInZcvAy7k2sDn9K8X+L2lW9jLb6np8VxA32gxM0ikEsFBDZ9cg19BSKGudqkYA+Q9eRXnHxos5bvwjcK0nzJcI8FuiZd3JwQT34J6UAcJD4v8AFOoeFHt7jQVvdOkQoJ1hfJI/izznnOan8N/Fm703QotOOk/aZ7cFRJvOMf7Qx2rmvCHjOTRbL7BNBEYRvKSgsHQt2yD06npWV/acd9rzS3t1cQWk5xPIh+ZwB1OB3Pt3oA6TX/iN4h1uF4hNFYWjZDeSCvHoTyT+FYXhyye91ZV0y0e/ePDSO+OOfvBT+mal1bXtJ/sa50vSdJVFkcEXcjfPgEHgf/XroPgJp73vjOSX5hFBbMWKnHJIAH8/yoA9k8L+HbTSEW7kicXByfPuWy4XrkDOFHtV6zWXXp1ihjlktYWJbLlVc5/iA6/SsrVBNr3jD/hHrKacW1rGkt5KGGATyE+vtXpukaRbWNlHBCrCNRxluT65oAz/AOz7CBI4LqytvLDA7TGCM+vNbEfkQSYRFJI42D/OKbf2FtPAwkUKQOGJ6GsqNNQJEcQcRrx9fpQBuSXLhAZXSNPTqTVVpH1B/KiGUHOW6Uy30mVnD3IJGeQGFbkMccEQC7UXHSgDLunvLSOPy7UXAyAdhAYD15rTtULwLIzNg8lQelNvJMBI1cK8nv2q0kqIigKOyjrn8KALECLIzLGQwC5yy1bW1jUEuoyD95j29ePamyyRwW7OzLGx4G3qTjpj1qpGhuXQTr5cHUR78Z92/wAKAJZAdS/dIWWzH325Bk9h7VprawCARhFVOBhf61C0iLhlI8tRg46DpViMrzk5BoAqSWEfmAMCwJ4ZVwV+pHWrkVrHEcjcWPBLHJNS9woOPalb64FACgLtI/Ck2rndj5vWlHAxTwuArHkH0oAFUYzyB1/Gh8hsjkZx0p4Jz0AyfzoORgADPbBoAaV4AIO4ego2LkkAAH0FPxnA35zRt2jA4GfWgBUII+U8ClA68Y7U0cY2kY7gUgJzxnPYkUAS/QYFeQftU61/Y/wev4El8ufU5orRPVhu3uP++UI/GvXVBGQMcV8l/tq6+tx4h8P6DGwP2O3e6l/3pCAo/AJn/gVAHzXRRRQAUUUUAFFFFABRRRQB6/8AAHxHHY3V9pN1kRy4uI37KR8rZ+o2/lXvC+XKoMUoKnB4IxXx74W1ZtC1+y1EJ5iwvmSP++h4ZfxBNfQVxep9ut7SxZ0sNTjxtfBwCOwzxkUAd8kkNxGxUrKp43LzTTKVjCEDK8AP3qvodrZ6Xp9vaWvyxxLtCBc1rYSRTgHA4xjoaAMa6sxcW7yxlo5FP/LNyBmsDxJKkp01b3IZJi0TkYZXVTgH1ya3vE/iLT9A8kXvmGWVhsghjMkjfRRzXlHxG+Ib29zaxDSfJl3CYw3bZcr23KDhc/Un2oAseO/AFheaZb3dlYPbXquDcPDg71P3n25weefXrXC+Jfhve2MkP9hytq0cvOI0AZRgEE8n1rdPxWsjp5U6Lsu8HBjlO0fXPOK5K98b3x0iLT7A+Qnl7ZZQMSMSecEdBQByksbQyvHIMOjFWGc4Ir0n4I63p2h32rz6lLKh8hWRY0LF9pOQMd+RUXwi0XRJNQTV/EWpadHDA+IrSaZQzt/eZSeg/WvfdG0LwlJcm70210tpmO4tCVJJ9SAcUAM+E+lz2Ggz6lqcbJqOrTtezKw5QN9xT9FxXoZfZCCeuOMVmi5AQqPmcdMU61uWmvPIaMKFUOCfSgC9Hbee2+cZPUKei/hUzsRIqxZ4HJUdKaqk53twOeOKcACp/hJ5OD+lAD1Un/lqw+rdaVYUYZO5sjhpDkGk3FkzGo4p8QJILtk9cDtQAkdlGvllWYSL/FjP4fSpGF6oBhMDgdA4IzU8b+WOh3e/FW4ZIyoWRSWJwVHPA6UAUbOGcS+feAE9AEwVX8+9aolVI9pWbC+qg1HtgUqzbirZx6DmraqhwY+AOOmCcdqAIDKpTbHE0gGDyvFW7Is1upePZzgL3HpUkaDIJ/LFS0AAGPWlIyORxSjr/hR0JoAAcZ9xilUjr0I/Wm96fjB6c8fhQAqZB69cd6VcEEKQCf0oPCnI/wDrU3IAII464PY0APwwA5HA7Gk7biDg/epRlcZXnGAQaXacBT07mgBIwx535FKQcY4UeuaQIQGznGO3emvzgk5+vFADmdVRpJHEcaAlmJ4AHJJzX5yfFHxKfF/xA1vXMFY7q4PlLuziNcKn/jqivsH9pjxe3hj4X3sEMm2+1hjYw4zkIR+8Yc9l4+rCvhSgAooooAKKKKACiiigAooooAK9z+Cklv4h8P3GlsxTVLBvMSQtlmj/AIcZ7Kcg+xWvDK3fBPiGfwt4mstVt8sIXxLGD/rIzwy/l09wKAPqe11nVNOga2v9Kubi5QYWS3XIkPY+1SrH4n1dUUQ2+j2Z5cuRLcPkdsfKtdPpF3b6hp9ve2kgkguI1ljcd1IyKvKpY4FAHO6V4fs9JVmgRnuXOXuJTukc9+T/ACFfMHxp0rULHx7qdzewyiC5cPDKQdrLgAAH2xjHtX2A8RPboetZeo6daam09tqFvHNBJHtKSKCGB68UAfC1FfV+q/B3wfO4f7BNbAHk28zAH6g5A/Cn2vwi8Haf+9j05ruQHKrcTM6nj0BAoA+Takgmlt5BJBI8Ug6MjFSPxFfXk3gPwtIY4rnw5p8anglYPLxx6jk15T8WfhENIgfVfCySSWaDdNa5LtGP7ynqR6g80AW/hT8RLrULuDTdSvUW9OVjac4SX2B7N+hr2+1+2K0bBEDdXKnfn8TXw6rFWDKSGByCDgg19R/BDxrL4j0Rre/IbULIBHYnmRcfKx9+CPwoA9XjuxPCdvJHBHofSp1fcxb+ED14rj9d8T6J4blE+q6glqJxwh5ZiP8AZHJp/h3x54d1ybZp2oJK47FSvP4igDsk+Y4/KriJkYBH0rNSUO2QflPA96sQM3BUHPQ5oAuhTk4YZ71PErKVJPQ5B4OPSqaSE8EjI7irETtknjjmgDRjKOmHRcheAMZP4VYiXIBC4J/P8aq2RZ5GYnOAAeOTV8Lk5bPXHPWgCWMfKOc06moMLjOcUpOMUAOxkcfnT1A7Yz05pobA6Z+tLnceuB6UAIODnAI9ccU5AAQRknvikAIA4B9qcvp0BPI70ACcHA4P9007aGYsDyOKGbIYKM0DhiMjJ9KAFQMMcn15FOB9RzTULFTnrnFBbg5INACk/KcA59KTG5iOnTOabvHJ55HPSvIf2kviMPBHg5rDTpF/trV0eGDHWGIjDy/XnC+/PagD5t/aP8cL40+ItwLORn0vTAbO2z0YgnzHH+82cH0C15VRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHun7O/jo290PDGqzjyJMtZSSOfkfvEM8YPJHvx3r6NgPBwR+NfACO0bq8bFXU5VlOCD6ivrj4O/EKLxlpH2e6ZY9btEAnjHHmr0Ei/1HY/UUAeoxgHIOB6n0qrPahm7f4U+Nz0bBP5VPGNx64I6UAZstlJswXcqRj1qvZ6csdwHaV3boM9BW6I24BPy+1V57cqQUPX8MUAQ3EZZFU7W9OOhqlLAZFZXjymOcGrbOzDB5pI38uMo+MdjQB8pfHLwKfDGtLqVjEV0q+Y4AORHL1K/Q9R+PpXGeD/E1/4U1U32mMvmFGjZHyVYEcZHfBwa+vvGOi2HifQ7nSL1cxyjIYdY2HRh7ivl3W/hf4o07VntLfTJ72ItiKeFcrIPXrx9DQByms6re61qEt9qdzJcXMn3nc9vQeg9q6r4eyTRTBwsu1TndztHtXpPwx+CbxyLqPjKNCRzHYBs4PrIRx+Az7+leqa34R02XR7iOwtILWVU3IY0CjI9cUAN8EasZ7WKKdj5nbPWvQLZMp79smvkXRvH95pV2XuCzJG+CF6DB719VaBexahpNrdR5KzxLIO3BANAGkQdpOBj1qSA7cgDBPTtUG4tgfw+tSRruOdxBoA0rJA2SQfl6HPf/OK0UyQVIOD0NULfcOY2Xaedmc/mavRhtpyPbjnFAE46UDrSLnHIpwODkUAKCPlxnNPUBWG3kEetR7jkHPIpysRzn+VAD9wBBYHP6UyTg45/Ghmy1IWyBnORQBIHwowOB3pdwCgle+ai3dePpT0cFcHg+1ADmw6g4xSfLkbmPHIoyW5VuT2prlgTngdeewoAzfEWtWXhzQ77WdXlMVlZxGWR++B0AHdicADuSK/Pn4neMrrx34zv9cu1aOOVtlvAWyIYV4RPy5PqST3r0T9pT4rHxlrJ0DQ51bw5YS58yPpdzAYL5/ujJC9jyecjHiFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWhoOr3ug6tbalpkxhu7d9yMOnuCO4I4I9Kz6KAPtH4beOdO8aaOlxbssd9GoF1ak/NE3qPVSeh/DrXaW8vz89Sc8V8IeF/EGo+GNZh1PR5/Juo8jkZV1PVWHcGvrX4deP8ATPGunCS2It9RjXNxZs2WQ/3ge6+/50AegbyDkHr2qT5nUZIANUVkYbckYqSOUnjJyfTtQBFdR87kJBOTgVVd87QwI9RV+Q/wgZz69KquqlicYoApyFFHIXOOwqS3DbgSefpSMuG7fX1qeIZJ2DI9RQBZijJUEnDZ69ao+ILhNP0S/uZNuIoHbPuAcVdRtr/M2RXnX7QOtPpnw8u0Qqst3Iluu7qQTk4/AUAfKSTTS3zKz5aV8E9sk19wfDmP7N4H0ONnzIlpGrHtwK+EcnduzznOa+8fAUcsPhDR4p1xItpFu+u0UAdEo3HKj5etTRDg4yBmoRxjHWp0YMM9DngZ60AW4IyjhyCeN2AecfnWlHuIIBA9T3rKSTaYt65Ucrg+/wDn8q0IHJjycjPI+nagC3nkenenAZOBUaPuOP1zT6ADryetKBk470h5oyep60AOXHII6D6UmDgZzig5zyc0q5OBnj0z1oAdGvOTnPbjipAMN24HWmlhkEnkdiKj3ErjjAGcntQBITuK8EnPbjivlb9pT40C6S68HeE7hWt+YtRvomyJPWFD/d7Me/TpnLv2gPjuZVn8NeBbtljG6K+1GMYLdVMcR9OuXHXt6n5hoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAq7pGp3uj6hFfaXcy2t3EcrJGcEe3uPY8GqVFAH1T8K/i7ZeKEi0zXWhsNXAAViQsVx/u56N/s9+3oPV1JZto+X6cV+f9ewfDj42anoJW08Sefq1hwqyl/38I+p++PZj+NAH1IkYb+E5Pr1qVYw/y4GPSsnwz4j0rxLp63uhXsV1CfvbDhkPoynlT9RW7G2RjvjmgCq0I3gsi9OM0NGv90VOwxIS3T2pj84OevbPSgCq6lcA9MYzXzr+1HfzPf6Lp4P7iON5iPVicD9Afzr6WkVdo4PT8K+P/wBoa8Nz8S7yINlbaKOIDsDjcf8A0KgDifCemNrPifStOQZNzcxxn2BYZP5Zr7y0+HyYkjH3UXaK+Pf2foYJfippJucYjEroD3YI2P6n8K+zolXAAwFoAcFwckcfSpcElVQZGacijaAOT2wOtWLJVLDcF68DuCKAJoYThkdc85yMd8ZFWPK2NwNvbAHHf/GkZSTwcEd+1PoAUMQc96nDBuAffiqxIXljgdzUEl4qtwpznsBQBpd6TOM/y71ViuTPnZkYqde2F+o7igCUYB+bpSk54A4/pUJYkkAZHQ8V5J8Ufjj4f8DiSy09o9a1oEqbeCX93D7yOMjP+yMn1xQB6d4i13TfDmjzanrl5FZWEP3pZTwT2AHUsewHJr48+NnxyvvGyyaRoCzad4fDEOd5WW7GMfvMHAXr8v5157498eeIPHWoi78Q3zTBM+TboNkUIPZVH8zknuTXLUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBe0jVr/AEa9S70q8ntLlCCJIXKng5wfUcdDxXuXgj9oKaJBbeMLQzDgC7s0Ab33ITg/UY+lfP8ARQB94+GfF+g+KbZbnRdRguR0MYbbKnP8SHDD8q2nZeQBgivz2jdo3V42ZHU5DKcEGvRPDXxk8YaGERr5NRt0AURXqb+B/tDDfr2oA+xdwK4I6dMV8UfGWUy/E7xCxJOLnbz2woFev6F+0Tp8oVNd0S4tzzmS1lEgzgfwtgjv3PavCPG+pQax4v1jUbV2e3ubl5I2ZdpKk8ZHbigDvf2Z7Vbj4iSO65ENjK30JZV/qa+u4MBQD1x3FfKn7LJA8Z6mSUA+wkZYgfxrX1bbI0iBogXGeoGR+YoAsqF8sHdz/dxVmCXDM0mD2LAcj8u1VQsnAaNge3HWpCj7ABE3fJx1oA0kJbpjkdjTsqgbeOnNVjdR25AuHigOBjewUE45xn0rj9d+InheyneG98SaXAVco0ZuAzBh1yFyaAOqlna8nEcIBQHpj/PFXYbNEX5yWYjBzXjV/wDtC+A9HtmOnyX+qz8fLBbmMHr3fH8q858R/tRa5cpJH4f0Ow08Nwstw7XEg9wPlXPXqCKAPqW7his43uzMlvFGMu8jBUH1J4Ary/xr8fPCXhkNBb3La1qC8GKxIMan3lPH5ZNfIvirxx4m8V4HiHW72+QHIjkfEYPHRBhR0HauboA9P+IXxs8XeM45bWS5XTdLcn/RLLKbh2Dv95vzA9q8woooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKu2eq6jZReXZ393bx5ztimZBn1wDVKigDZXxT4gU5XXdVB9ryT/ABpt14l127gMN3rWpzwkhtkt3Iy5HQ4JrIooAlmuJp9vnzSSbem9icfnUVFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angiogram obtained after the AVM seen in prior radiograph was treated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Guy Rordorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_1_38943=[""].join("\n");
var outline_f38_1_38943=null;
